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2. LIST OF ABBREVIATIONS 
 In accordance with HUGO Gene Nomenclature Committee and Mouse Genome 
Database guidelines, proteins are written in upper case, human gene symbols and 
transcripts are indicated upper case and italicized while rodent gene symbols and 
transcripts are indicated first-letter upper case and italicized. 
 
(a)CSF  (artificial) cerebrospinal fluid 
BAT   brown adipose tissue 
CDS   coding DNA sequence 
CRE   cAMP response element 
CREB   cAMP response element-binding protein 
D1   type 1 iodothyronine deiodinase protein 
D2   type 2 iodothyronine deiodinase protein 
D3   type 3 iodothyronine deiodinase protein 
DIO1/Dio1  gene or mRNA of human/rodent type 1 iodothyronine deiodinase 
DIO2/Dio2  gene or mRNA of human/rodent type 2 iodothyronine deiodinase 
DIO3/Dio3  gene or mRNA of human/rodent type 3 iodothyronine deiodinase 
E1   ubiquitin activating enzyme 
E2   ubiquitin conjugating enzyme 
E3   ubiquitin ligase enzyme 
ECFP  enhanced cyan fluorescent protein 
EERI   Eeyarestatin I 
ERAD  endoplasmic-reticulum-associated degradation 
EYFP  enhanced yellow fluorescent protein 
FRET  fluorescence (Förster) resonance energy transfer 
HPT axis  hypothalamo-pituitary-thyroid axis 
KM   Michaelis-Menten constant 
LPS   lipopolysaccharide 
MARCH6  Membrane-Associated Ring Finger (C3HC4) 6  
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mCherry  monomeric modified red fluorescent protein 
MG132  proteasome inhibitor (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) 
NF-κB  nuclear factor κ-light-chain-enhancer of activated B cells 
p65   subunit of the NF-κB transcription factor 
PACAP  pituitary adenylate cyclase-activating polypeptide 
PKA   protein kinase A 
PVN   paraventricular nucleus 
Sec   selenocysteine 
SHH   Sonic hedgehog 
SP1   specificity protein 1 
T3   3,3’,5-triiodo-L-thyronine 
rT3   3,3’,5’-triiodo-L-thyronine 
T4   thyroxine, 3,3’,5,5’-tetraiodo-L-thyronine 
TH   thyroid hormone 
TR   thyroid hormone nuclear receptor 
TRE   thyroid hormone response element 
TSS   transcriptional start site 
Ub   ubiquitin 
UPS   ubiquitin-proteasome system 
UTR    untranslated region 
WSB1   WD40 SOCS-box containing protein  
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3. INTRODUCTION 
3.1. SIGNIFICANCE AND ACTION OF THYROID HORMONES 
3.1.1. General aspects of thyroid hormone action in the brain 
 Thyroid hormones (THs) play essential role in the regulation of a wide range of 
biological phenomena and fundamentally affect the metabolic and developmental 
processes. THs exert a major impact on brain development and function, discussed in 
section 3.1.3 in more detail [1]. Furthermore, the level of TH in specific brain regions has 
far-reaching consequences on various peripheral organ systems [2]. Thus, understanding 
cellular and molecular mechanisms regulating TH levels in the brain is a great importance 
both for brain-related and peripheral processes. 
 Specific features of multiple regulatory levels need to be taken into account when 
the complex framework of TH economy is discussed. First, the primary product of human 
thyroid gland is the stable prohormone thyroxine (T4) that cannot be efficiently bound by 
the thyroid hormone nuclear receptors (TRs) on the canonical ligand-binding pocket [3]. 
Therefore T4 is not able to modulate gene expression via the canonical, TR-mediated 
pathway of TH action [4]. The regulatory capacity of hypothalamo-pituitary-thyroid 
(HPT) axis is restricted predominantly to the synthesis and release of the T4 prohormone. 
Second, mostly T4 can be transported via the blood-brain and CSF-brain barrier while the 
transcriptionally active, circulating serum T3 has poor access to most of the areas of the 
central nervous system due to the selective affinity of TH transporters (Fig. 1) [5]. Taken 
together, the HPT axis has obvious limitations and is insufficient to control TH action in 
the brain. Third, and as a consequence, TH action in the brain requires the local 
conversion of T4 to T3 that is critical in the TH-dependent modulation of gene expression. 
The metabolism of THs is catalyzed by members of the deiodinase enzyme family 
allowing both the activation and inactivation of THs. Exclusively the type 2 deiodinase 
(D2) is expressed as activating deiodinase in the human brain and D2 is the main source 
of the T3 in the central nervous system [6, 7]. 
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Figure 1. Limitations of the HPT axis in the regulation of local thyroid hormone action 
The thyroid hormone receptor binds T3 with high affinity but thyroid hormone transporters of the blood-
brain barrier have low permeability for T3 that makes local activation essential for thyroid hormone action 
in the brain. 
 
 Importantly, TH metabolism in the brain is highly compartmentalized. While D2 is 
expressed exclusively in glial cells – in astrocytes and hypothalamic tanycytes – the 
neurons are not able to activate THs, the glial-derived T3 affects the neuronal 
transcriptome on a paracrine manner. However, neurons are able to modulate their 
intracellular TH level via type 3 deiodinase (D3) catalyzed inactivation [8]. Therefore the 
control of TH mediated gene expression in the brain requires the coordinated actions of 
TH transport and deiodinase-mediated TH metabolism (Fig. 2). These processes are 
especially significant in the regulation of the HPT axis as they result not only in local but 
also systemic changes in TH economy via the control of negative feedback of TRH 
neurons, see in section 3.1.4. 
 
 
Figure 2. Thyroid hormone metabolism 
Activation and inactivation pathways are catalyzed by the members of deiodinase enzyme family via 
removal of iodine from the outer or inner ring of thyroid hormone derivatives, respectively. 
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 In conclusion, the interaction between deiodinase-mediated TH activation in the 
brain and the HPT axis represents a core mechanism of controlling TH economy thorough 
the body. Thus, we focused our studies to better understand the molecular regulation of 
TH activation and its impact on the HPT axis. The following sections provide a brief 
overview on different regulatory levels of TH action including the mechanism of TH 
transport and TRs followed by the introduction of the role THs in the central nervous 
system (CNS) and the periphery. The second part will focus on the deiodinase-mediated 
metabolism of THs – especially the activation by D2 – and the regulation of the D2 
enzyme. 
 
3.1.2. Mechanism of thyroid hormone action: transporters and receptors 
 TRs – exerting the canonical TH effect – selectively bind T3 as ligand therefore the 
precise control of intracellular availability of T3 directly affects the exerted effects of TH. 
This regulation requires the contribution of thyroid hormone transporters (both at the 
blood- brain barrier and at paracrine transport between glial and neuronal cells) and 
thyroid hormone metabolizing enzymes, deiodinases. The coordinated action of 
transporters and deiodinases also provides the opportunity of fine-tuning of T3 availability 
at the cellular level and determining the liganded state of TRs (Fig. 3) [9]. 
 
 
 
Figure 3. Thyroid hormone metabolism in the brain 
Schematic depiction of the thyroid hormone availability in the brain based on the neuro-glial 
compartmentalization of thyroid hormone transport and metabolism. 
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 According to the old dogma, THs as lipophilic molecules were thought to undergo 
passive membrane transport upon their passage through the plasmamembrane into the 
cytosol without the involvement of active transport. However, this idea was disproved by 
the identification of different types of thyroid hormone transporters that allowed the 
specific transport of TH through the plasmamembrane [10, 11]. The importance of active 
TH transport is clearly demonstrated in the Allan-Herndon-Dudley syndrome (AHDS) 
leads to a mixed thyroid phenotype with mental retardation, central hypotonia and 
impaired auditory development [12]. AHDS is caused by mutations in thyroid hormone 
transporter SLC16A2 (MCT8) belongs to the monocarboxylate transporter (MCT) family 
along with SLC16A10 (MCT10). SLC16A2 is capable to transport both T4 and T3 while 
SLC16A10 has selective binding for T3 [5]. SLC16A2 is widely expressed in the CNS 
including neurons, glial cells and capillaries [13]. 
 The second class of thyroid hormone transporters is the large family of organic 
anion-transporting polypeptides (OATPs). The selectivity of SLCO1C1 for T4 over T3 
and its enriched expression in endothelial cells of capillaries could underline the unequal 
permeability of the blood-brain barrier for TH derivatives [13]. Additionally, while the 
SLCO1C1 knock-out mouse has a mild phenotype [14], its combined deletion with 
SLC16A2 resembles the developmental abnormalities of AHDS in human [15]. L-amino 
acid transporter (LAT) family is also capable for TH transport SLC7A2 (LAT1) and 
SLC7A8 (LAT2) are identified as TH transporters however their in vivo importance in 
TH transport are much less characterized compared to the above mentioned transporters 
[5]. 
 The canonical and most studied pathway of TH action is mediated by transcriptional 
events via the TRs [4]. In contrast to other nuclear receptors, e.g. the estrogen receptor 
and glucocorticoid receptor, TRs are located predominantly in the nucleus even in 
unliganded form. The general TR structure contains the following domains in order from 
N-terminus to C-terminus: N-terminal activator (A/B), DNA-binding (C), hinge region 
(D), ligand-binding and dimerization (E), C-terminal activator (F) (Fig. 4) [16]. Two TR 
encoding genes were identified (THRA and THRB) each of these has three transcript 
variants [17]. TRα1, TRα2 and TRα3 are transcribed from THRA gene however only 
TRα1 has classical receptor functions while TRα2 and TRα3 lack the T3-binding ability 
due its alternatively spliced C-terminus and abolished T3- 
DOI:10.14753/SE.2016.1924
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Figure 4. Schematic structure of thyroid hormone nuclear receptors 
Amino acid position refers for human orthologues; note the alternative splicing of the C-terminus of TRα2 
and TRα3 results in abolished ligand binding. 
 
binding pocket [17, 18]. Additionally, a downstream alternative transcriptional start site 
within THRA gene results in a truncated transcripts similarly to TRα2 lacking the T3-
binding capacity. TRs bind one T3 molecule prior to activation. While a recent study 
indicated an additional ligand-binding surface within TRα1 that shows selectivity for T4 
however the importance of this site is remained to be confirmed [19]. The THRB gene has 
three transcript variants: TRβ1, TRβ2 and TRβ3. Based on crystal structure data a second 
ligand binding surface could be formed by TRβ at least for the TRβ-specific T3-analogue 
GC-24 [20]. Beside the canonical genomic effects of TRs TRβ was demonstrated to 
modulate the phosphatidylinositol-3-kinase (PI3K) pathway and affect HIF-1α level via 
non-translational manner. The importance of this pathway is poorly understood yet. 
 The model of TH action suggests that TR-mediated regulation of gene expression 
is based on the altered interaction profile for cofactors upon T3-binding. This current 
model is based on the activation of well conserved positive thyroid hormone response 
elements (TREs) in the genome while the negative action of TH’s is much less 
understood. The prediction of the TR binding sites for negative regulation is not 
conclusive. In the absence of T3, TRs bind to TRE and recruit histone deacetylases e.g. 
nuclear receptor corepressor (NCoR1) and silencing mediator of retinoic acid and thyroid 
hormone receptors (SMRT, NCoR2) [21]. The binding of T3 alters the equilibrium 
between the monomeric-dimeric states and allows the heterodimerization with retinoid 
X-receptor (RXR). This transition leads to the release of repressor complex and harboring 
activator proteins including histone acetyltransferases (steroid receptor coactivator-1 and 
2, SRC1, SRC2 or NCoA1/2) and p300 (Fig. 5) [22]. In case of a negative TRE the T3 
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induced binding of TR represses promoter activity however the precise mechanism of 
action of THs on negative TRE is poorly characterized. 
 TRα is expressed in most tissues including the brain, cardiac and skeletal muscle, 
intestine and bone. TRβ1 has also wide expression profile e.g. in the brain and liver while 
TRβ2 is the predominant isoform in the hypothalamus and pituitary, consequently plays 
a crucial in the TH-feedback of HPT axis [23]. The differential expression has also 
clinical significance providing the opportunity of tissue-specific targeting of TH action 
using TRα- or TRβ-selective agonists or antagonists. Mutations in TR proteins can lead 
to the manifestation of the Resistance to thyroid hormone (RTH) syndrome hallmarked 
by altered TH-binding capacity causing symptoms of hyperactivity, emotional alterations 
and mental deficit on different levels of severity. Most known cases involve mutation(s) 
in TRβ [24] but recently TRα mutant patients have been also revealed [25-27]. 
 Extranuclear, non-canonical TRs have been also discovered. Mitochondrial 
processes are major target of TH action and the p43 protein was identified as a 
mitochondrial TR [28, 29]. Under specific conditions the kinetics and the cell 
permeability independent nature of TH action suggested the existence of thyroid hormone 
membrane receptors that could govern genome-independent action. Integrin αVβ3 was 
identified as a cell membrane located receptor showing specific binding for T4 [30]. This 
cascade activates the MAPK signalization that results in phosphorylation of TRβ and 
increasing its transcriptional activity [31]. 
 
 
 
Figure 5. Schematic model of the activation of thyroid hormone receptors by ligand binding 
TR: thyroid hormone receptor; TRE: thyroid hormone response element (DR4 type); HDAC: histone 
deacetylase; NCoR: nuclear corepressor; NCoA: nuclear coactivator; H: histone; Ac: acetyl group. 
DOI:10.14753/SE.2016.1924
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3.1.3. The biological significance of thyroid hormones  
3.1.3.1. Brain 
 THs are crucial regulators of developmental programs and their role in neural 
development is clearly demonstrated by symptoms caused by various defects of different 
events of TH action. Congenital hypothyroidism requires on-time TH supplementation to 
avoid irreversible developmental brain deficits. Promoting the exit from cell cycle and 
affecting differentiation programs THs are major regulators of progenitor cell 
development. Altered TH synthesis, metabolism or transport result in dramatic effects on 
neuronal differentiation and maturation manifested in significant loss in cognitive 
functions [1, 32]. Numerous genes with specific roles played in brain development are 
regulated by THs. Expression of crucial factors that organize the migration and survive 
of precursor cells like reelin, brain-derived neurotropic factor (BDNF) and nerve growth 
factor (NGF) are under the regulation of THs [33-35]. Oligodendrocyte differentiation, 
myelination and axonal growth are proved to be sensitive to TH status via the involvement 
of crucial genes like myelin basic protein (MBP) and myelin-associated glycoprotein 
(MAG) that are transcriptionally upregulated by THs [36, 37]. Expression of 
synaptotagmin – a protein involved in the docking and fusion of synaptic vesicles – is 
also affected by THs [38] suggesting a general mechanism how THs are able to influence 
neural communication. 
 Cerebellar development, foliation, maturation and migration of cerebellar neurons 
are strongly affected by THs via TRα [39, 40]. Dendritic arborization of Purkinje cells is 
also controlled by THs [39]. Delayed maturation and abnormal migration of granular cells 
was observed while the maturation of Bergmann glia and GABAergic interneurons were 
also affected in TRα dominant negative mutant mice [41]. These developmental processes 
reflect to the mechanistic background of impacted motoric phenotype in hypothyroidism 
observed both in human and animal models with deficiencies on different levels of TH 
signaling [40]. Normal cerebellar development requires the rapid supplementation of TH 
in congenital hypothyroidism. 
 Decreased mental capacity by hypothyroidism is associated with impaired learning 
and memory as broad range of hippocampal functions are controlled by THs. Synaptic 
remodeling, excitability, associative learning and inhibitory inputs for hippocampal cells 
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are also affected by THs [42]. Timing of the developmental phases of new-born neurons 
is controlled by coordinated TR expression [43]. Affected mood and behavior in patients 
with altered TH state is underlined by the connection between THs and the molecular 
elements of serotoninergic system [44]. THs are in tight interaction with other 
neurosecretory systems both in the hypothalamus and the pituitary. Reproductive 
functions are targeted by local TH metabolism in the hypothalamus by the regulation of 
seasonal activity [45, 46] and lactation [47, 48]. TH levels also affect stress response and 
anxiety, CRH expression is stimulated by THs [49-51]. 
 Proper TH signaling is also essential in the sensory system. THs are crucial in the 
development of auditory system as found in congenital hypothyroidism or in Allan-
Herndon-Dudley syndrome with severe deficits or complete loss of hearing [12]. Both 
the morphogenesis and function of the auditory system requires precise control of local 
TH transport and metabolism [52-55]. Improper TH level results in delayed program of 
eye development, eye opening and retina morphogenesis probably via altered 
mitochondrial biogenesis [56]. THs are also important regulators of opsin expression and 
patterning, defects in TH signaling results in reprogramming of M-opsin cones to S type 
[57, 58]. 
 
3.1.3.2. Peripheral organs 
 THs increase mitochondrial activity and elevate the metabolic rate both on cellular 
and systemic level [59, 60]. Alterations in TH actions directly affect energy homeostasis 
and could serve as a source of several clinical symptoms. In hypothyroidism, the basal 
metabolism is decreased and consequently energy consumption is reduced that can be 
manifested in weight gain while hyperthyroidism has the opposite effect on energy 
homeostasis. Liver has crucial function in chemical energy storage, conversion and 
transport therefore hepatic transcriptome is a major target of TH actions. THs are also 
crucial factors in the central regulation of energy balance. Genes involved in lipolysis, 
lipogenesis, fatty acid transport and gluconeogenesis were shown to be under TH control. 
The clinical significance of this regulation is demonstrated by impaired liver metabolism 
in altered TH status [61]. THs also affect the cardiovascular system and cardiac 
metabolism increasing heart rate and volume while hyperthyroidism leads to cardiac 
muscle hypertrophy. THs contribute to the regulation of skeletal muscle metabolism and 
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substrate preference of chemical energy production while hypothyroidism manifested in 
decreased muscle tone [62]. 
 The brown adipose tissue (BAT) is a well-documented target of THs involved in 
the maintenance of body temperature in hypothermic condition, especially in rodents 
[63]. While this function is also important in human neonates, until the last decade it was 
thought that thermogenesis by BAT is absent in human adults due to the documented 
regression of BAT depos. However, a few years ago the presence of functionally active 
BAT islands was identified in the skeletal muscle by PET imaging [64-66]. Recent studies 
suggest that these depots belong to the beige adipose tissue derived from different 
progenitors compared to BAT [67-69]. Human BAT or beige fat could have clinical 
significance since experimental data demonstrated the induction of beige adipose tissue 
by drugs used for treatment of type 2 diabetes [68]. Therefore in adult humans these cells 
could play an important role in maintaining body energy balance rather than protecting 
body temperature. 
 The thermogenesis is an alternative route in mitochondria to use the electrochemical 
energy of proton gradient between the two sides of the inner membrane. In this process 
the protons are not transferred through the ATP synthase but carried by the uncoupling 
protein 1 (UCP1 or thermogenin) into the mitochondrial matrix. Therefore the 
electrochemical energy generated by oxidative phosphorylation is converted to thermal 
energy instead of storage in chemical energy by ATP. After the discovery of UCP1 
homologue proteins have been also identified and shown to be expressed in several tissues 
including the hypothalamus however the exact function and uncoupling capacity of these 
UCP’s are remained to be clarified similarly to the exact mechanism of heat generation 
by shuffling H+-ions into the mitochondrial matrix. 
 The BAT is under the control of the sympathetic nervous system by noradrenergic 
stimulation predominantly via β3-adrenergic receptor [70]. The selective agonists of this 
receptor evoke the activation of BAT and induction of the differentiation of beige cells in 
white adipose tissue [71]. Induction of heat production is controlled by the noradrenergic 
stimulus-driven activation of cAMP second messenger system resulting in upregulation 
of Ucp1 transcription and lipolytic enzymes. The release of fatty acids by lipoprotein 
lipase from triglycerides is also increased by elevation of intracellular cAMP and serves 
both as fuel and also as cofactor for UCP1. TH contributes to elevated UCP1 level and T3 
DOI:10.14753/SE.2016.1924
 14 
production is elevated by the cAMP-mediated induction of the Dio2 gene, see also in 
3.2.2.1. As a consequence, hypothyroidism results in severe deficits in adaptive 
thermogenesis. [72]. 
 
3.1.4. The hypothalamo-pituitary-thyroid (HPT) axis 
 The synthesis and release of THs are controlled by the HPT axis. The HPT axis 
consists of hypophysiotropic TRH neurons of the paraventricular nucleus, thyroid-
stimulating hormone (TSH) secreting cells of the adenohypophysis and the thyroid gland 
itself. The precise control is supported by multilevel negative feedback of the axis (Fig. 
6). 
 Hypophysiotropic TRH neurons are located in the paraventricular nucleus (PVN) 
of the hypothalamus sending axon terminals to the portal vessels of the median eminence 
and regulating the TSH synthesis and secretion of the adenohypophysis. We summarize 
below how THs are able to modulate TRH expression along with distinct peptidergic 
inputs on TRH neurons. TRH gene encodes a precursor protein (preproTRH) containing 
five copies of TRH. The precursor is processed by endopeptidases (prohormone 
convertase, PC) cleaving the three amino acid-long TRH peptide. TRH contains N-
terminal pyroglutamate and its C-terminus is amidated (pGlu-His-Pro-NH2). These 
modifications are obligatory for the active peptide. PC1 expression and pyroglutamyl 
peptidase (PPII) – cleaves the pyroglutamate at the N-terminus – is regulated by THs [73-
76]. The TRH gene contains several TREs therefore directly responsive to TH via TRβ2 
receptors [77-80]. 
 Hypothalamic T3 concentration is controlled by local activation and inactivation of 
TH but TH economy in this brain region is more complex than in the rest of the brain. 
The reason is that the blood-brain barrier in the median eminence – the region below the 
floor of the third ventricle – is incomplete. Therefore hypothalamic TH levels are affected 
both by local TH metabolism, tanycytic D2, neuronal D3 and by circulating T3 (Fig. 6). 
Thus T3 input of TRH neurons are coming from both local and peripheral sources. The 
balance between these two T3 sources can be shifted towards locally generated T3 by 
tanycytic D2 under specific circumstances as clearly demonstrated in the infection-
evoked rodent model of non-thyroidal illness. In this model, despite falling  
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Figure 6. Schematic depiction of thyroid hormone feedback of the HPT axis 
Involvement of thyroid hormone metabolism in the regulation of HPT axis. 
 
serum TH levels, the upregulated tanycytic D2 activity results in local hypothalamic 
hyperthyroidism that leads to the suppression of HPT axis and hypothyroid peripheral 
status [81]. Therefore D2 activity in tanycytes is under strict control that includes the 
posttranslational ubiquitin-proteasome system (UPS), see in section 3.3. Factors that 
modulate tanycytic D2 activity have the potential to directly affect the HPT axis [82]. 
Beside their crucial role of T3-production tanycytes are capable to affect TRH neurons by 
several ways. As mentioned above PPII inactivates TRH and tanycytes express PPII that 
is regulated by THs [75, 76]. Tanycyte processes terminate on the capillaries of the 
median eminence and form a dynamic barrier for the axon terminals that release hormone-
secreting neurons as observed in case of TRH [83] and GnRH neurons [84]. 
 The TRH promoter cAMP-response element (CRE), glucocorticoid response 
element (GRE), STAT3 and SP1 binding sites [85, 86]. These pathways transmit crucial 
peptidergic signals involved in the regulation of energy homeostasis. TRH cells receive 
information from the orexigenic NPY/AgRP- and anorectic αMSH/CART-containing 
neurons in the arcuate nucleus sensing humoral signals including insulin, leptin, glucose 
and ghrelin [87]. Recent studies revealed that cells coexpressing TRH and pituitary 
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adenylate cyclase-activating peptide (PACAP) in the PVN send stimulatory inputs to the 
inhibitory AgRP cells of the arcuate nucleus providing a short feedback loop for TRH 
cells [88]. TRH neurons are innervated by the hypothalamic dorsomedial nucleus and the 
adrenergic nuclei of the brainstem; afferents from the last region contain CART, NPY 
and PACAP peptides [89-91]. 
 The axons of TRH neurons project to the median eminence where release to the 
portal system and stimulate the TSH expression and secretion of thyrotropic cells in the 
adenohypophysis (Fig. 6). This occurs via the type I TRH receptor [92] and by the 
involvement of the activation of phospholipase C pathway inducing Ca2+-release and 
activation of CAMK-mediated CREB phosphorylation [93]. TSH is a heterodimer of 
thyrotropin-specific TSHβ and TSHα (CGA) that is a common subunit of chorionic 
gonadotropin (CG), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and 
TSH. Both α and β subunit expression are stimulated by TRH via CRE sites and inhibited 
by TH via negative TREs that results in a short feedback-loop [94, 95]. Importantly, these 
hormones are glycoproteins and the amount and pattern of carbohydrates highly affects 
their stability and bioactivity that posttranslational modifications are sensitive for TRH 
[96, 97]. TSH glycosylation was also shown to be sensitive for T3 and its secretion and 
bioactivity is also affected by deletion of Dio2 gene [98, 99] indicating that the short 
feedback loop of HPT axis also requires the local T3 generation via D2. 
 In the thyroid gland the activated TSH receptor (TSHR) induces cAMP production 
and PI3K activation [100, 101] stimulating the transcription of genes involved in TH 
synthesis including I- uptake by Na+/I- symporter (NIS) [102], thyroglobulin [103] thyroid 
peroxidase (TPO) [104] and I--recycling by iodotyrosine dehalogenase (DEHAL1) [105]. 
 
3.2. DEIODINASE ENZYME FAMILY 
3.2.1. Structure and biochemistry of deiodinases 
  THs are metabolized by a specialized oxidoreductase enzyme family called 
iodothyronine deiodinases. Deiodinases are different both in structure, catalytic 
mechanism and function from iodotyrosine deiodinases involved in the recirculation of 
iodine in the thyroid gland. As a common feature, deiodinases contain a rare amino acid; 
selenocysteine (Sec), often referred as 21th amino acid. While the exact catalytic 
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mechanism is not completely understood it has been established that based on larger 
atomic radius, Sec is much more efficiently ionized at physiological pH than cysteine that 
represents a major advantage to catalyze oxidoreductive processes, like deiodination. As 
a result, the presence of Sec increases the affinity for substrate robustly. Its replacement 
with Cys results in a ~1000-fold elevated KM of D2 for T4 along with a highly increased 
translation [106]. Thus the presence of Sec in deiodinases results in high substrate affinity 
and low protein level. Deiodinases has the ability to catalyze the loss of iodine both of 
the outer and inner ring of thyronine backbone (Fig 2.). The incorporation of Sec is carried 
out by a complex apparatus during the translation (Fig. 7) [107]. Unlike the common 20 
amino acids, Sec is encoded by the UGA STOP codon that is subjected to read-through 
in selenoproteins. This process requires the presence of a specific mRNA secondary loop 
structure called selenocysteine insertion sequence (SECIS) element in the 3’-untranslated 
region of the selenoprotein encoding mRNA. The SECIS-loop is bound by SECIS binding 
protein 2 (SBP2) that interacts with the special elongation factor eEFSec allowing the 
recruitment of the tRNA specific for Sec. In contrast to the common amino acids Sec is 
synthetized on its transfer RNA (tRNASec). The tRNASec is loaded with a serine then the 
hydroxyl-group of serine is edited to selenol-group by enzymatic cascade [108]. 
Available clinical data demonstrated that mutations in SBP2 affects the TH metabolism 
and reported impaired response for T4 but not for T3 [109]. In summary, this sophisticated 
system allows the cotranslational incorporation of a special amino acid Sec into 
selenoproteins by a complex and energy-dependent manner. 
 
 
Figure 7. Synthesis and cotranslational insertion of selenocysteine into selenoproteins 
EFSec: Selenocysteine-specific elongation factor; SBP2: SECIS-binding protein 2. 
 
3.2.1.1. Type 1 iodothyronine deiodinase (D1) 
 D1 is encoded by the DIO1 gene located on the chromosome 1p32 in human and 
by the homologous Dio1 gene in mouse on the chromosome 4. DIO1 gene contains 4 
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exons; exon 1 contains the translational start ATG codon after a short, 25 nucleotide-
lengths 5’-untranslated region (UTR) [110]. Exon 2 encodes the catalytic selenocysteine 
and exon 4 carries the SECIS region within the 3’-UTR which is crucial in the insertion 
of selenocysteine amino acid during the translation. 
 The product of the DIO1 gene is a 249 amino acid-lengths type I membrane protein 
located in the plasmamembrane, with 26-30 kDa molecular weight. As a common feature 
of deiodinases D1 forms dimer which is obligatory for active conformation. The three 
dimensional structure of D1 has not been resolved yet therefore the domain structure and 
catalytic mechanism are based on predictions and sequence homologies. D1 shows highly 
conserved amino acid sequence between species. The N-terminus of D1 contains a short 
extracellular-tail composed from approximately the first 10 amino acids followed by the 
transmembrane helix located between amino acid position 10 and 40. Despite of the fact 
that D1 is highly conserved between species the first region of the cytosolic globular 
domain between amino acid position 40 and 70 shows variability (Fig. 8) [111]. 
Importantly, within this region there is a short deletion in feline and canine D1, two 
species where the biochemical properties of D1 are slightly different compared to other 
mammals [112, 113]. The globular domain contains the active center and the catalytic 
selenocysteine in the amino acid position 126. The region spans the active center is highly 
conserved between homologues and orthologue deiodinases. 
 
Figure 8. Alignment of human D1, D2 and D3 proteins and the predicted domain structure 
 D1 has the ability to catalyze both outer- (ORD) and inner-ring deiodination (IRD) 
that is unique compared to the other members of deiodinase enzyme family. Therefore 
both the activation an inactivation of thyroxin (ORD and IRD of T4) are catalyzed by D1 
with the affinity for substrate KM ≈ 10-6 M in both cases which is slightly higher compared 
to the same values of D1 for the IRD of T3. However the affinity for IRD of rT3 is one 
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order of magnitude lower (KM ≈ 10-7 M) suggesting this derivative is the preferred 
substrate of D1. While the catalytic mechanism of deiodinases is poorly understood, 
interestingly the conserved deletion in case of feline and canine D1 revealed the 
importance of this region in the IRD of rT3. In case of this species the KM is elevated to 
~10-5 M. 6-n-propyl-2-thiouracil (PTU) competes with the reducing agent of D1 while 
has a minimal effect on the other two deiodinases this effect has both clinical and 
methodological importance. 
 D1 is expressed in various tissues and cell types but importantly not in the human 
central nervous system. The most abundant D1 expression was found in liver, kidney and 
intestine while its activity is also present in the thyroid gland, pituitary and other tissues 
depending on the developmental stage. It is important to note that in contrast to the other 
two deiodinases D1 is not restricted to either the activation or inactivation of HTs 
therefore its expression and activity has to be evaluated in accordance with thyroid status 
and the available substrates. Hepatic D1 contributes to circulating T3 in hyperthyroidism 
while under euthyroid conditions D1 deiodinates predominantly rT3 as demonstrated in 
the Dio1 KO mice that shows slightly elevated T4 level while rT3 level is increased 3-fold 
[114]. 
 Available data are limited on the regulation of the DIO1 gene however it was 
demonstrated that its transcription is positively regulated by T3 [115]. This attribute of 
D1 explains the relatively larger contribution of liver D1 to the circulating T3 in 
hyperthyroid conditions which is sensitive to PTU. Thyroidal but not the liver D1 was 
shown to be modulated by TSH-driven cAMP however it is unlikely that this effect is 
driven by the cAMP-sensitivity of DIO1 gene [116]. Similar asymmetry was observed in 
case of selenium-deficiency which results in decreased hepatic and renal D1 activity 
while thyroidal and pituitary D1 is slightly affected [117]. The energy balance, steroids 
and circadian rhythm are also showed to affect D1 activity however it is unlikely to be a 
specific and direct effect on DIO1 gene. There is no evidence to have posttranslational 
modification on D1 protein. In contrast with D2 that is targeted by the ubiquitin-
proteasome system D1 is not ubiquitinated and has longer half-life [118]. 
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3.2.1.2. Type 2 iodothyronine deiodinase (D2) 
 Type 2 deiodinase (D2) is encoded by the DIO2 gene in human and located on 
chromosome 14q24 while Dio2 gene on chromosome 12 in mouse. DIO2 gene contains 
two exons separated by a ~7.4 kb intron. Three transcription start sites (TSS) [119] were 
found in DIO2 gene affecting the unusually long 5’-UTR of the mRNA. Five splice 
variants of human DIO2 gene were identified that show differences in the insertion of two 
portions of the intron and the termination of translation. The alternatively spliced mRNA 
forms encode four different putative proteins [120]. The 5’-UTR of DIO2 mRNA contains 
upstream/short open reading frames (uORF or sORF) in different species, and not their 
number (3-5) but their existence is conserved between species (Fig. 9). The uORF-A 
affects the translation efficiency of the DIO2 coding sequence (CDS) and helps to keep 
D2 protein level low due to represent a translational roadblock during ribosomal scanning 
[121]. The DIO2 mRNA has a 5 kb 3’-UTR containing the SECIS-loop at the 3’-end. The 
3’-UTR segment between the D2 CDS and SECIS-loop contributes to the instability of 
the DIO2 mRNA [121] however the accurate mechanism of this phenomenon is not yet 
resolved. 
 
 
Figure 9. Structure of DIO2 gene and splice variants 
uORF: upstream open reading frame; UTR: untranslated region; TSS: transcription start site; SECIS: 
selenocysteine insertion sequence. 
 
 Despite the unusual length of the DIO2 mRNA (6-7.5 kb in vertebrates) the D2 
protein is encoded by an only ~800 kb long coding region generating a 31 kDa type I 
membrane protein, localized in the ER in stable retention. Similarly to the other members 
of deiodinase family, D2 also forms homodimers and this structure is obligatory for the 
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active conformation of the enzyme. D2 has a short ER-lumen localized N-terminal tail 
followed by the transmembrane domain between amino acid position 20 and 40. The 
transmembrane domain plays an important role in the dimerization of D2 via ionic 
interaction between helixes. Based on homology and hydrophobicity predictions the TM 
domain is followed by a cytosolic linker region and thioredixin-fold βαβ motif between 
amino acid 122 and 163 [122]. The catalytic selenocysteine amino acid is localized within 
this domain in position 133 of human D2 which is followed by iodothyronine-deiodinase 
active center motif localized between amino acid 164 and 192. The C-terminus of the 
protein contains a variable and ββα thioredoxin motif between 193-224 and 225-273 
amino acids, respectively. Unlike D1 and D3, D2 contains a second UGA close to its C-
terminus at codon position 266, however the second Sec residue is not required for 
catalytic activity of the enzyme (Fig. 8) [123]. 
 Point mutations that alter amino acid in the D2 protein were identified but their 
significance is still poorly understood [124-126]. These polymorphisms include L4H, 
T92A and T102I amino acid changes. L4H and T102 seem to have identical properties 
compared to abundant allele of D2 [125]. Interestingly, T92A is suggested to be in 
correlation with numerous symptoms e.g. type 2 diabetes mellitus, Graves’ disease, 
mental abnormalities, affected bone and muscle metabolism etc. however most of these 
studies are controversial and restricted to clinical data [124]. It is also remained to be 
clarified whether the statistical correlation is underlined by the effect of T92A 
polymorphism via modified biochemical characteristics of D2 or this polymorphism is a 
linked genetic marker of other mutations in same region of chromosome [124, 127-130]. 
While the precise background of the effect T92A polymorphism is poorly understood it 
is important to note that the 92th amino acid position is within the previously identified 
instability-loop of D2 involved in its posttranslational regulation by ubiquitin-proteasome 
system. 
 In contrast to D1, the catalytic activity of D2 is restricted to ORD of TH derivatives. 
The mechanism of deiodination and the structural basis of the difference between D2 and 
D1 are incompletely understood. However, there are major differences between the 
biochemical properties between the two T4 activating deiodinases, D2 and D1. First, the 
primary substrate of D2 is T4 and has three orders of magnitude lower, ~10
-9 M in vitro 
KM for this molecule, than that of D1. D2 is also effective in the deiodination of rT3 
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indicating that the structural differences between D1 and D2 result in higher catalytic 
efficiency. The importance of selenocysteine played in the catalytic mechanism of 
deiodinases was demonstrated clearly for D2; the mutation of this residue to cysteine 
results three orders of magnitude higher KM for T4 [106]. The homologue mutation in D1 
leads to only one order of magnitude increase in KM for the preferred substrate rT3 [131]. 
Importantly, the studies targeting the biochemical characteristics of deiodinases were 
performed in cell lysates not using purified enzymes therefore the comparisons between 
different studies should be read carefully. 
 D2 is widely distributed in different tissues and its function is primarily the local 
T3 generation compared to D1. Importantly, D2 is the activating deiodinase in central 
nervous tissue and its expression is confined to glial cell types. High D2 activity was 
described in pituitary [98] while high DIO2 mRNA level in thyroid [132]. Another 
important target organ is the brown adipose tissue (BAT) where the D2-driven T3 
increases the noradrenergic signal stimulated UCP1 expression. Probably due the 
common lineage, similarly to BAT, D2 refers for T3 generation in skeletal muscle, and 
seems to be important in tissue regeneration after injury [133]. D2 was also found in 
cardiac muscle, lung [134], perinatal liver and skin. 
 The complex regulation of D2 is summarized in section 3.2.2. 
 
3.2.1.3. Type 3 iodothyronine deiodinase (D3) 
 D3 is encoded by the DIO3 gene located on chromosome 14q32 in human. The 
homologue chromosome region belongs to the Dlk1-Dio3 imprinted locus in mouse on 
chromosome 12 and D3 is preferentially expressed from the paternal allele [135], at least 
at the periphery, while in the brain Dio3 imprinting is region specific [136]. DIO3 gene 
contains one exon and the predominant DIO3 transcript is 2.1 kb however there were 
identified alternative transcription start sites that result in different transcript sizes [137-
139]. These forms do not affect the coding sequence however in low abundance an 
alternative translation initiation methionine containing transcript was identified resulting 
26 amino acid elongation of the N-terminal extracellular tail. The abundance of 
alternative transcripts is dependent on thyroid status. Additionally, the DIO3 locus is also 
transcribed in antisense orientation named as DIO3OS pseudogene however its translation 
to protein is controversial [139]. 
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 D3 is a 32 kDa type I membrane protein located in the plasma membrane with its 
C-terminus in the cytosol forming homodimers [140, 141]. Similarly to D1 and D2, D3 
has a short N-terminal tail followed by transmembrane region that was suggested between 
amino acids 29 and 49. The predicted domain structure of D3 shows high similarity to the 
other two member of the enzyme family. The first crystallized data on deiodinase 
structure was recently obtained on the D3 globular domain fragment [142]. These results 
confirm the thioredoxin- and peroxiredoxin-fold homology and the insertion of 
iodothyronine deiodinase-specific helix-loop-β-sheet organization with critical function 
in the TH binding. D3, similarly to D1, contains one selenocysteine residue in amino acid 
position 162 of human D3 (Fig. 8). Posttranslational modification of D3 is not indicated 
by the presently available data. 
 The catalytic action of D3 is restricted to IRD therefore the inactivation of THs. D3 
has nearly equal affinity for T3 and T4 (KM=1-2 nM and 4-5 nM, respectively) therefore 
it has the ability to reduce directly the thyroid prohormone compound without its 
activation [122]. The recently obtained structural data allowed to constitute the model of 
catalytic mechanism of D3 and – based on the conserved structure of deiodinases – also 
helped to better understand the principle of deiodination catalyzed by D1 or D2. This 
study revealed the presence of conserved amino acids with a predicted proton-shuttle 
function and importance in the protonation of carbonyl atom after elimination of 
iodoninium by selenate. It has been suggested that the regeneration of active center 
requires a two-step mechanism: in the first phase it is reduced by the formation of an 
intramolecular disulfide-bond which is reduced by the endogenous cofactor of 
deiodinases remained to be identified. This mechanism seems to be non-functional for 
D2 since this enzyme lacks the required C-terminal cysteine [142]. D3 is also insensitive 
for PTU [110]. 
 D3 is expressed in neurons in the CNS cells where it inactivates T3 generated by 
glial D2. In Dio3 KO mice the abolished clearance of T3 by D3 results in severe 
thyrotoxicosis in perinatal life leading to central hypothyroidism via suppressed HPT axis 
[143]. Placental and uterine D3 is crucial in supporting the independent thyroid state of 
embryos from the maternal environment [144]. D3 is also expressed in liver and intestine 
especially in the embryonic days involved in the control of fetal TH environment. High 
D3 activity could be detected in skin and reproductive organs [145]. 
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 In the CNS the DIO3 transcription shows high sensitivity for the thyroid state which 
serves as a negative feedback toward the transcriptionally active TH [138]. In the placenta 
and uterus DIO3 is strongly correlated with estrogen and progesterone levels these 
hormones have a synergistic effect on DIO3 translation at least within this region [146]. 
The DIO3 is directly upregulated by HIF-1α in response of hypoxic condition to locally 
decrease the energy and oxygen consumption via inactivating T3 [147]. 
 
3.2.2. Regulation of type 2 deiodinase (D2) 
3.2.2.1. Transcriptional regulation of D2 
 The regulation of D2 is the best characterized among deiodinases (Fig. 10). D2 is 
sensitive to intracellular cAMP level and a functional CRE was identified within the 5’ 
flanking region (5’ FR) of both the human DIO2, and the rat and mouse Dio2 genes 
showing that D2 expression is directly targeted by cAMP-driven CREB phosphorylation 
(Fig. 11) [119, 148, 149]. Beside the induction of DIO2 promoter, the cAMP/PKA 
pathway is also an important regulator of the basal promoter activity of DIO2 gene 
demonstrated by the mutation of cAMP response element (CRE) that resulted in 
decreased basal promoter activity by one order of magnitude [119]. Despite the crucial 
role of cAMP/PKA pathway in the regulation of DIO2 transcription only a few upstream 
factors have been revealed elevating D2 activity via this pathway. During the induction 
of adaptive thermogenesis in brawn adipose tissue (BAT) the noradrenergic stimulus via 
β3 adrenergic receptors promotes intracellular cAMP production and increases D2 
expression. The elevated T3 generation contributes to the induction and increase of UCP1 
level [150]. The adrenergic stimulus also targets D2 in the pineal gland regulating the 
photoperiodic alterations in TH activation [151]. In birds  
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Figure 10. Regulatory levels of D2 activity 
Schematic depiction of elements involved in the transcriptional, posttranscriptional and posttranslational 
regulation of D2 activity. 
 
and mammals, the hypothalamic TH metabolism is in tight correlation with the seasonal 
regulation of gonads and reproductive axis and D2 expression is under the control of 
TSHβ derived from pars tuberalis [152-154]. However, the importance of cAMP-
mediated regulation of D2 in tanycytes is poorly understood especially in aspects of HPT 
axis. 
 The human DIO2 gene was shown to be a positive target for NF-κB pathway as the 
overexpression of p65 subunit of NF-κB results robust increase of DIO2 promoter activity 
(Fig. 11) [155]. This pathway plays a major role in the bacterial lipopolysaccharide (LPS) 
infection-induced suppression of the HPT axis via the induction of D2 activity in 
tanycytes that results in the inhibition of TRH neurons. This mechanism generates local 
hypothalamic hyperthyroidism and uncouples local TH levels from the peripheral TH 
economy in non-thyroidal illness [81, 156]. In cultured tanycytes LPS was able to induce 
D2 and the inhibition of the NF-κB pathway completely abolished this effect [157]. 
 In contrast to the conserved responsiveness to cAMP and NF-κB, the DIO2 
promoter shows species-specific response to other factors e.g. the human DIO2 but not 
the rat Dio2 gene was found to be responsive to TTF1 (Nkx2.1) [149] and this could 
underline the strikingly different D2 levels in the human vs rat thyroid gland (Fig. 11). A 
similar phenomenon was observed regarding GATA-4 and Nkx2.5. Human DIO2 is  
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Figure 11. Transcriptional regulation of D2 
Transcription factor binding sites in the promoter of the human DIO2 gene. 
 
affected by these factors while rat Dio2 is not sensitive. This mechanism is suggested to 
explain the difference in D2 expression in case of cardiac muscle of these two species 
[158]. 
 D2 expression was showed to be inversely regulated by THs in the cortex however 
direct transcriptional effect is remained to be elucidated because the lack of evidences for 
negative TRE in the promoter region of DIO2 gene [159]. 
 These examples reveal the complex transcriptional regulation of the DIO2 gene 
encoding D2 that is affected by several pathways. However little known how these 
signaling cascades and factors affect D2 in vivo, especially in hypothalamus where the 
local T3 generation has crucial impact on the HPT axis. 
 
3.2.2.2. Posttranscriptional regulation of D2 
 The 5’-UTR of DIO2 mRNA contains uORFs and these are able to decrease the 
efficiency of D2 translation that allows keeping D2 protein at low level that contributes 
to the tight regulation of D2 activity (Fig. 10) [121]. The 5’-UTR structure can be 
subjected to alternative splicing that provides an additional mechanism to regulate the 
efficiency of DIO2 translation but the physiological significance of this mechanism 
remains to be understood (Fig. 9) [119]. The DIO2 mRNA has very long 3’-UTR (4-5 
kb) and contains RNA instability motifs that contribute to the short half-life of DIO2 
mRNA [121]. 
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3.2.2.3. Posttranslational regulation of D2 
 As a unique feature among deiodinases, D2 activity is subjected to complex 
posttranslational control by the ubiquitin-proteasome system. The mechanism of this 
regulatory pathway is summarized in section 3.3. The short half-life of D2 protein is 
caused by ubiquitin-mediated proteasomal degradation (Fig. 10) [118]. The D2 is 
processed by an E3 ligase complex organized by the Cullin5 E3 ligase backbone and 
Elongin B and C adaptor proteins. The WSB1 SOCS-box protein binds to Elongin B and 
C and refers for the recognition of D2 by this complex (ECSWSB1). The ubiquitin is carried 
by the UBE2J (Ubc6) and UBE2G (Ubc7) E2 enzymes [160, 161]. This machinery is 
strongly associated to D2 homodimers on the cytosolic surface of ER and allows a precise 
control of D2 activity on T4-dependent manner therefore the D2 is also targeted by TH 
control on the posttranslational level (Fig. 12). The substrate induced ubiquitination of 
D2 represented the first example of this type of regulation of hormonal activity via an ER 
resident enzyme [118]. 
 
 
 
Figure 12. Schematic model of ubiquitinating apparatus in close association with D2 in the ER 
Cullin5: scaffold protein; Rbx1, Elongin B and C: adaptors; WSB1: SOCS-box substrate-binding subunit; 
UBEG2 (Ubc7): E2 ubiquitin conjugating enzyme; CUE1P: anchoring and activator protein of UBEG2. 
 
DOI:10.14753/SE.2016.1924
 28 
 Importantly, this system is capable to downregulate the D2 activity without 
degradation of the protein which is favorable in case of a selenoprotein that requires an 
energy-dependent insertion of the rare amino acid selenocysteine. The ubiquitination of 
D2 protein results a conformational change that abolishes the enzyme activity [162]. The 
ubiquitinated inactive state of D2 could be reversed by deubiquitinating enzymes via the 
cleavage of ubiquitin chain resulting regained activity. Previous studies identified the 
USP33 (VDU1) and USP20 (VDU2) proteins with the capability to deubiquitinate the D2 
[163]. The recognition of D2 by ECSWSB1 is facilitated by T4, the 
 substrate of D2, demonstrating a unique regulation of enzyme activity. Moreover the T4-
dependent reversible inactivation of D2 allows a rapid and efficient way to fine-tune the 
TH activation capacity. Beside the ECSWSB1 complex, recent studies based on yeast two 
hybrid screen identified the MARCH6 (TEB4, mammalian orthologue of Doa10 in yeast) 
ERAD ubiquitin ligase as potential E3 enzyme for D2 [164]. 
 As previously mentioned, the ubiquitination is a unique feature of D2 among 
deiodinases however the background of the difference is not clearly understood. Previous 
studies identified critical elements involved in the short half-life and ubiquitination of D2 
protein. It is also remained to be elucidated how ubiquitin ligases contributes to the 
regulation of D2. Specific features of D2 ubiquitination has been suggested in the 
hypothalamus with major impact on TH replacement therapy [82, 165]. Therefore 
detailed molecular characterization of D2 ubiquitination is essential to better understand 
the regulation of hypothalamic TH activation. The crucial components of the ubiquitin-
proteasome system will be summarized below. 
 
3.3. THE UBIQUITIN-PROTEASOME SYSTEM 
3.3.1. Mechanism of ubiquitin-conjugation 
 The ubiquitin-proteasome system (UPS) was discovered as a complex machinery 
dedicated to targeted intracellular proteolysis that impacts a wide range of cellular 
processes e.g. cell division, signal transduction, gene regulation and ER quality control 
(endoplasmic reticulum-associated degradation, ERAD) [166]. Further studies on the 
UPS revealed that it is more accurate to distinguish between the ubiquitin tagging and 
proteasomal degradation since only a subclass of ubiquitinated proteins is degraded by 
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proteasome. The ubiquitin is an evolutionary conserved small, 8.5 kDa protein containing 
76 amino acid residues containing seven lysines and C-terminal glycine-glycine residues. 
It is important to note these features serve as the structural basics of the diversity of 
ubiquitin signal as described below. 
In the first step the ubiquitin-activating enzyme (E1) catalyzes the formation of an 
ester linkage between adenosine-monophosphate from ATP and the C-terminal glycine 
of ubiquitin followed by direct conjugation of ubiquitin to a cysteine residue of the E1 
enzyme by thioester linkage resulting a high-energy reactive bound (Fig. 13). In the most 
of the species only a single gene encodes E1 suggesting that the role of the E1 enzyme is 
restricted to the universal activation step of the ubiquitin moiety and has a limited effect 
on its further processing or target selection [167]. 
 The action of E1 is followed by the transfer of ubiquitin to a cysteine residue of 
ubiquitin-conjugating enzyme (E2) via formation of a thioester linkage. In contrast to E1 
there are multiple E2 enzymes with specific expression, localization and different 
mechanisms of action (Fig. 13). The core catalytic domain of E2’s is highly conserved 
but some of them contain N- or C- terminal extension that affects their localization or 
interaction with E3 ligases [167]. While the function of E1 enzymes is restricted to 
supporting the energetic background of ubiquitin conjugation some of E2 sterically 
determinates or restricts the ubiquitin conjugation process. 
 
 
Figure 13. Mechanism of ubiquitin conjugation 
Ub: ubiquitin; E1: ubiquitin activating enzyme; E2: ubiquitin conjugating enzyme; E3: ubiquitin ligase 
(complex); S: substrate protein. 
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 The most diverse component of the ubiquitinating apparatus consists of E3 ligases; 
there are hundreds of proteins with ubiquitin ligase function. E3 enzymes catalyze the 
formation of isopeptide-bound between the C-terminal carboxyl-group of ubiquitin 
moiety and ε-amino-group on one or more lysine residues of target protein, the second 
often referred as multiubiquitination. Importantly, the E3 ligases have the ability to extend 
the initial ubiquitin by the addition of further ubiquitin moieties result polyubiquitin chain 
formation. The quantity and quality of these chains substantially determinate the way of 
downstream processing of the target protein (Fig. 13). 
 The E3 ligases can be grouped into three classes based on the mechanism of 
ubiquitin-transfer and structural properties. HECT-type (homologue to E6-AP carboxyl-
terminus) ligases form a covalent bond between one of their cysteine residue and ubiquitin 
therefore the ubiquitin is not directly attached to the target protein. The other two groups 
similarly bind the ubiquitin-carrier E2 and transfer ubiquitin directly to the substrate 
protein. The vast majority of E3 enzymes is RING-type (homologue to the Zn-finger of 
“really interesting new gene”) coordinating two Zn2+-ion which are involved in the 
stabilization of RING-domain. In contrast, the U-box E3 ligases have a structurally 
similar domain to RING but lack the metal-binding ability. 
 Most of the RING-finger E3 ligases have modular multiprotein structure splitting 
the major functions (scaffolding the complex, binding E2 and recognizing substrate) 
between different protein chains [168]. In case of Cullin-based ligases these functions are 
carried out separately. The core unit of the complex is the Cullin lacking the ability to 
bind to ubiquitin-loaded E2 that is carried out by Rbx proteins. Another part of the 
complex refers for the substrate recognition e.g. F-box and SOCS-proteins which are 
connected to the Cullin-organized complex via Skp1 or Elongin B and C adaptor proteins 
[169]. This modular scheme allows the precise combination of target selection with the 
type of conjugated ubiquitin chain. 
 The fused ubiquitin or ubiquitin chain determinate the fate of the substrate protein 
and its degradation in the proteasome represents only one possibility. The exact 
understanding of ubiquitin code is one of the most important issues related to the UPS 
function. The single ubiquitin or ubiquitin chain and in the last case the structure of the 
chain result a major difference in the acceptability for ubiquitin-binding proteins which 
stands in the structural background of the linkage between ubiquitin signal synthesis and 
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function. Other theories raised the possibility that the difference is based on molecular 
dynamic aspects which are determined by the orientation of proximal and distal ubiquitin 
within the ubiquitin chain [170]. 
 While the soluble proteins in the cytosol could reach the proteasome directly after 
tagged by degradative ubiquitin signal, the ER membrane proteins have to undergo a 
complex process to access to the proteasome. This includes the cleavage of degradative 
ubiquitin signal partial unfolding and transport to the cytosol where new degradative 
signal is synthetized for these proteins. The core member to organize this machinery is 
the p97/VCP complex. The importance of this system is to support the accessibility of 
proteasome for ER-proteins [171]. 
 
3.3.2. Cleavage of ubiquitin: the deubiquitinases 
 The ubiquitin chain synthetizing apparatus allows the selective labelling of proteins 
resulting precise targeting of their action that is fine-tuned by the reversibility of 
ubiquitin-mediated modification. This system allows a reversible posttranslational 
modification of protein function, localization, stability and importantly the 
recircularization of ubiquitin. The latter is critical within the cell demonstrated by the 
inhibition of the proteasome (e.g. by MG132) that contains subunits with deubiquitinase 
activity for cleavage of polyubiquitin chain from substrates. Inhibition of this process 
leads to ubiquitin “depletion” and interferes with ubiquitin-conjugation [172]. Because 
de novo ubiquitin synthesis is not able to compensate the inhibition of ubiquitin recycling 
this condition has severe toxicity for the cell. Importantly, de novo ubiquitin synthesis is 
also requires the cleavage of ubiquitin because the four genes encode ubiquitin in repeated 
copies of ubiquitin or ubiquitin is translated in fusion to other proteins and in all of the 
cases ubiquitin moiety is released after cleavage [173, 174]. Deubiquitination is also 
involved in the extraction of ER-localized proteins to the cytosol ensuring the unfolding 
of target proteins which are reubiquitinated after reaching the cytosol. 
 Deubiquitinases (ubiquitin-specific proteases, USPs) are cysteine- or 
metalloproteases with the ability to cleave ubiquitin or ubiquitin chain at different sites. 
The cleavage site could be determined by the docking surface on deubiquitinases, linkage 
type of ubiquitin chain and also by the substrate [175]. These capabilities allow a broad 
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range of action of deubiquitinases including the rescue from degradation, allowing chain-
editing or transport. 
 
3.3.3. Importance of ubiquitin-ubiquitin linkage 
 All of the seven lysine residues of ubiquitin and also the N-terminal amino-group 
could be involved in the formation of a polyubiquitin chain but only the K48- and K63-
linked chains are well characterized. The following section briefly addresses the 
diversities of protein processing by different ubiquitin linkages. 
 Despite of lacking evidences on the exact role of K6 ubiquitination this type of 
ubiquitin chain seems to exert non-degradative functions. K6-linked polyubiquitin chain 
synthesis is involved in the recognition of DNA damage and the recruitment of repair 
machinery recognized by Werner helicase interacting protein 1 (WRNIP1) [176, 177]. 
Cytoskeletal dynamics and remodeling are affected by K6-mediated ubiquitination of α-
tubulin [178]. 
 K11-linked ubiquitin chain possesses proteolytic functions and its essential role was 
demonstrated in endoplasmic reticulum associated degradation (ERAD). In other cases, 
K11 ubiquitin chain formation interferes with K48-linked ubiquitination rescuing the 
target protein from degradation [179] or resulting partial proteolysis as in the case of Ci 
(insect orthologue of mammalian Gli proteins involved in Sonic hedgehog signalization). 
K11 ubiquitin chain synthesis is demonstrated in signaling pathways and cell cycle [180, 
181] Interestingly, Doa10 – the yeast orthologue of mammalian MARCH6 – is suggested 
to be involved in K11-linkage formation in combination with Ubc6 E2 enzyme [182]. 
Importantly, both of them are involved in the regulation of D2. 
  The K27-linked polyubiquitin chain is predominantly a non-degradative tag, 
involved in DNA damage response, histone-modification [183]. K27-linked ubiquitin 
chain is synthesized by Parkin ubiquitin ligase and shown to be involved in the turnover 
of mitochondria [184]. 
 Recently, only very limited data are available on processes modulated by K29-
linked ubiquitin chain exclusively and this type of action is often reported in mixed or not 
characterized ubiquitin chains. K29-chain is involved in the activation and regulation of 
the stability of β-catenin transcription factor modulator in Wnt pathway [185, 186]. 
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 The function of K33-linked chains is also poorly characterized but it was suggested 
to work as a non-degradative signal. The K33 signal affects actin assembling and cellular 
trafficking in trans-Golgi [187] and has a role in the regulation of TCR-ζ phosphorylation 
[188]. 
 There is no doubt that the K48-linked ubiquitin chain is the most characterized and 
understood linkage type. While other linkage types also can target proteins for 
proteasomal degradation, the K48-chain is the major functional linker of ubiquitin 
conjugation to proteasomal degradation, referred together as the ubiquitin-proteasome 
system [166, 189].  
 The K63-linked ubiquitin chain is the canonical example of non-degradative 
ubiquitin signals. The activation of NF-κB pathway requires K63-linked ubiquitin chain 
formation involved in IKK activation [190, 191]. This chain type is also involved in the 
response for double-strand break of DNA by the recruitment of the repair machinery [192] 
and play a role in intracellular trafficking and endocytosis [193]. 
 
3.3.4. The proteasome 
The proteasome is a multicatalytic protease complex with a fundamental role in 
several cellular functions. The subunits are organized into 4 rings forming a barrel 
structure. While the potential ancestral prokaryotic proteasome the HslU–HslV complex 
show hexameric symmetry [194] the eukaryotic proteasomes are common in the 
formation of heptameric rings [195]. The 20S core proteasome is built up by two outer 
rings formed by the α-subunits and two inner rings which are constituted by the β-
subunits. The α-rings have a gate keeper function – especially α3-subunit is critical in this 
aspect – and contribute to the conveying of unfolded proteins [196]. The β-rings carry the 
protease activities: β1 shows caspase-like, β2 trypsin-like and β5 chymotrypsin-like 
substrate preference. The proteasome has an important role in the process of antigen 
presentation by MHCI proteins via the generation of short oligopeptides. In case of 
immunoproteasome, the catalytic subunits are changed to β1i (LMP2), β2i (MECL) and 
β5i (LMP7) therefore the generated oligopeptides are optimized in the critical amino acid 
positions for binding into antigen pocket of MHCI [197]. Interestingly, genes encoding 
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β1i and β5i subunits are located in the MHC locus and deletion of these three 
immunoproteasome subunits leads to severely altered antigen presentation [198]. 
The 20S core proteasome carries the catalytic activity however the mature 
proteasome usually contains additional cap complexes. The most abundant lid structure 
is the 19S (PA700) subunit incorporating multiple functions. Similarly to 20S complex 
the 19S regulator has also ring-shape structure and it contains multiple subunits that can 
be divided into two major subclasses: ATPase (RPT) and non-ATPase (RPN) proteins. 
19S complex refers for the recognition and docking of polyubiquitin chain on target 
protein, unfolds the protein, and involved in the gating mechanism of 20S core 
proteasome. The complex of 19S and 20S is referred as 26S proteasome. 
 The 11S (PA28) subunit increases proteasomal activity although it restricts its 
acceptability to unfolded substrates. It is suggested that the 11S subunit is involved in 
MCHI antigen presentation by forming hybrid proteasomes with 19S subunit and docking 
it to the TAP1/2 proteins in the ER.  
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4. SPECIFIC AIMS 
 
 
1. Novel mechanisms regulating the HPT axis via D2-mediated thyroid hormone 
activation in the hypothalamus 
a) regulation of D2 transcription in the hypothalamus  
b) interaction between thyroid hormone and pituitary adenylate cyclase-
activating polypeptide (PACAP) signaling 
 
2. Involvement of MARCH6 ubiquitin ligase in the regulation of thyroid hormone 
activation 
a) tissue distribution and transcriptional regulation of MARCH6 gene 
b) characterization of D2-MARCH6 interaction 
 
3. Structural aspects of the ubiquitination of D2 protein 
a) combination of molecular elements required for the ubiquitin-mediated 
regulation of deiodinases 
b) structural background of the recognition of D2 by ubiquitin ligases 
c) importance of ER-membrane extraction in the reversible ubiquitin-
mediated regulation of D2 
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5. MATERIALS AND METHODS 
5.1. DNA constructs and RT-PCR 
5.1.1. Luciferase promoter constructs 
 DNA construct containing the human 7 kb DIO2 promoter in pGL3-basic vector 
(wtDIO2-Luc) expressing Firefly luciferase reporter was described earlier [155]. In order 
to generate cAMP-insensitive reporter construct site-directed mutagenesis was performed 
on the region containing CRE using overlap-extension PCR and primers indicated in 
Table 1. PCR fragment was inserted into wtDIO2-Luc construct using PacI-NheI sites 
resulting in CREmut-DIO2-Luc construct. Expression vector encoding mouse thyroid 
hormone receptor α (TRα) was described in [199]. 
 Plasmid encoding mouse Adcyap1 (PACAP) promoter driving luciferase reporter 
was a kind gift of Dr. Hashimoto (Osaka University) [200]. Plasmids containing 
constitutive active Gli2 (Gli2ΔN2) and octamer Gli-binding sites driving luciferase 
reporter used as positive control (8×Gli-BS) were kind gifts of Dr. Sasaki (Osaka 
University) [201]. The β-catenin containing expression vector and the human WSB 
promoter-luciferase reporter were kind gifts of Dr. Dentice [202]. 
 
Table 1. Primers designed for CRE mutation in the 7 kb 5’FR human DIO2 gene 
hDIO2 FW 5’-GCACCTACTGCTTAGCTTATG- 3’ 
hDIO2-mutCRE R 5’- AAGATCTTGtCGaCtTTGAGAAAGAGGGC-3’ 
hDIO2-mutCRE FW 5’-TTCTCAAaGtCGaCAAGATCTTTACCAAG-3’ 
pGL3-basic R 5’-TTCCATCTTCCAGCGGATAGA-3’ 
 
5.1.2. Tissue distribution of March6 
 Tissue samples were collected from adult male Wistar rats and total RNA was 
isolated using TRIzol reagent (Thermo, Waltham USA) following the manufacturer’s 
instructions. Reverse transcription to cDNA was performed using SuperScript II Reverse 
Transcriptase kit (Thermo, Waltham USA) and oligo dT. Intron-spanning primers were 
designed to amplify March6, Wsb1 and Ppia (Cyclophilin A) (Table 2) transcripts using 
Taq polymerase (Thermo, Waltham USA). PCR products were run in 1 % agarose gel 
and documented by Kodak Gel Logic 2200 Imaging System. 
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Table 2. Primers designed for detection of March6, Wsb1 and Ppia in rat tissue samples 
March6 FW 5’-GTGTCGGTCAGAAGGAACACCTGA-3’ 
March6 R 5’-AGTGATCCATCAAGTCCAAGCAT-3’ 
Wsb1 FW 5’-CGAGGGTCAACGAGAAAGAGAT-3’ 
WSb1 R 5’-GACGCAGTAGCTAGTAATGCT-3’ 
Ppia FW 5’-TGACTTCACACGCCATAATG-3’ 
Ppia R 5’-CCACAATGCTCATGCCTTC-3’ 
 
5.1.3. Cloning of human MARCH6 5’ flanking region 
 Genomic DNA was isolated from human HEK-293T cells using DNeasy Blood & 
Tissue Kit (Qiagen, Hilden Germany) and the 3.5 kb flanking region 5’ to the 
transcription start site (TSS) of MARCH6 gene was amplified using the primers indicated 
in Table 3 and Expand Long Range dNTPack (Roche, Basel Switzerland) following the 
manufacturer’s instructions. The generated amplicon was inserted between the MluI-
XhoI sites of pGL3-basic vector (Promega, Madison USA) that resulted in the MARCH6-
Luc construct. For deletion of the predicted SP1 binding site-containing 130 bp-length 
region the previously described construct was cut with SacII-XhoI, blunted and religated 
to generate the MARCH6-Δ130-Luc plasmid. The protein kinase A (PKA) α-catalytic 
subunit and the NF-κB subunit p65 encoding vectors were described previously in 
[119]and [155], respectively. 
 
Table 3. Primers designed for cloning the 3.5 kb 5’ FR of human MARCH6 gene 
MluI-hMARCH6 5’ FR FW 5’-tcgacgcgtGGAACAAGCTTCAGACCTGAGTCCACGTTAC-3’ 
XhoI-hMARCH6 5’ FR R 5’-ccgctcgagGGAGAGAGGCTGACAGAAAGCGAGCGACA-3’ 
 
5.1.4. FRET constructs 
 The human MARCH6 CDS-containing plasmid (pcDNA3.1-GFP-MARCH6) was 
used as a template (kind gift of Dr. M. Hochstrasser Yale University) for the generation 
of fusion proteins as follows. The EYFP-MARCH6 and ECFP-MARCH6 constructs were 
generated by the amplification of MARCH6 by Vent PCR (New England Biolabs) using 
the primers indicated in Table 4. Amplicon was inserted between the EcoRI-BamHI sites 
of pEYFP-C1 or pECFP-C1vectors (Clontech, Mountain View USA), respectively. The 
MARCH6-EYFP construct was generated by exchanging GFP in pcDNA3.1-GFP-
MARCH6 plasmid to EYFP using primers depicted in Table 4 and NheI-EcoRI sites. 
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Table 4. Primers used for cloning MARCH6 constructs for FRET measurements 
EcoRI-MARCH6 FW 5’-ggaattctattATGGACACCGCGGAGGAAGACATATGTAGA-3’ 
BamHI-MARCH6 R 5’-cgggatccTTATTCTTGGGATGACTGTGGAGGTGGTGGA-3’ 
NheI-EYFP FW 5’-ctagctagcATGGTGAGCAAGGGCGAGGAGCT-3’ 
EcoRI-EYFP R 5’-gaattccTTCGAA TTACTTGTACAGCTCGTCCATG-3’ 
 
 The WSB1-mCherry-SOCS fusion was generated by mutating STOP codon at the 
end of mCherry coding sequence (CDS) and inserting MluI site into pmCherry-N1 
(Clontech, Mountain View USA) vector. Full length CDS and SOCS-box region of mouse 
WSB1 was amplified by Vent PCR. Mouse WSB1 was inserted to the 5’-end of mCherry 
using EcoRI-KpnI sites while the SOCS-box region was cloned after the 3’-end of STOP-
codon mutant pmCherry-N1 between MluI-NotI sites. The used primers are summarized 
in Table 5. 
 
Table 5. Primers used for cloning WSB1 constructs for FRET measurements 
mCherry FW 5’-GAGCTGTACAAGTCACGCGTGCGGCCGCGACT-3’ 
mCherry R 5’-AGTCGCGGCCGCACGCGTGACTTGTACAGCTC-3’ 
EcoRI-Wsb1 FW 5’-ggaattcattATGGCCAGCTTTCCCCCGAGGGTTA-3’ 
KpnI-Wsb1 R 5’-ggggtaccgtACCGCGGTAGGAGAGAAACG-3’ 
MluI-Wsb1-SOCS FW 5’-tctacgcgtgtacAGGATTGTCCGGTAC-3’ 
NotI-Wsb1-SOCS R 5’-gcggccgcaCTAACCGCGGTAGGAGAG-3’ 
 
 D2-EYFP, D2-ECFP, ECFP-D2, WSB1-ECFP and EYFP-USP33 constructs were 
described in [162]. For FRET experiments applied to test the interactions between 
chimeric deiodinases and ubiquitin ligases the chimeras were subcloned into pEYFP-N1 
to generate C-terminal EYFP-fusion. Generation of chimeric deiodinases was described 
below. D2-T92A-EYFP construct was generated by overlap extension PCR on human D2 
using the primers depicted in Table 6 and cassette between internal AccI sites was 
exchanged in D2-EYFP construct resulting D2-T92A-EYFP, mutations indicated by 
lower case and underline. 
 
Table 6. Primers designed for D2-T92A construct for FRET measurements 
hDIO2 FW 5’- ggaattcattATGGGCATCCTCAGCGTAGACTTGCTGATCA -3’ 
hDIO2-T92A R 5’- GTCACCTCCTTCTGcACTGGAGACATGCA -3’ 
hDIO2-T92A FW 5’- GTGCATGTCTCCAGTgCAGAAGGAGGTGA -3’ 
hDIO2 R 5’- cgggatcccgACCAGCTAATCTAGTTTTCT -3’ 
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5.1.5. Generation of chimeric D1-D2 constructs 
 Cysteine-mutant rat D1 and human D2-containing vectors were described earlier 
[203]. Construction of chimeric deiodinases was based on the modification of cysteine-
mutant rat D1 using standard recombinant DNA techniques as described below. All 
constructs were cloned into a Tet-off system, D10 vector [204] and tagged by N-terminal 
FLAG-epitope. 
 D1-K and D1-2K constructs were generated by the insertion of P230K or 
R223K/P230K mutations into D1 using site-directed mutagenesis PCR using primers 
indicated in Table 7 and amplicon was inserted between the NheI and Bsu36I sites of the 
original rD1 construct. 
 
Table 7. Primers for generation of D1-D2 chimeras 
NheI-D1 FW 5’-ctagctagccATGGGGCTGTCCCAGCTATG-3’ 
D1 P230K R 
5’-CGGACTTCCTCAGGATTGTAGTTCCAAGGGCCcttTTTACCCTTGT-
3’ 
D1 
R223K/P230K 
R 
5’-TCGGACTTCCTCAGGATTGTAGTTCCAAGGGCCcttTTTACCCTTG 
TAGCAGATCtTGCCTTCCT-3’ 
D2-loop FW 5’-acagaaggaggtgacaacCAGAAGTGCAACGTCTGGGA-3’ 
D2-loop R 5’-gttgtcacctccttctgtTCCTGAGAGGCGGACCACGGT-3’ 
D1 R 
5’-ttccgcggccgctatggccgacgtcgacCTAGAACTGAGGCATGTGTCCAGG 
TGGGAT-3’ 
D1 FW 5’-ggaattcCCAGAGAGAGTCAAGCAGAACA-3’ 
D1 R 5’-ataagaatgcggccgcCTAGAACTGAGGCATGTGTCCA-3’ 
 
 To generate the D1-K-loop and D1-2K-loop constructs the aa. 92-97 region of 
human D2 was inserted into D1-K and D1-2K constructs – respectively – by overlap-
extension PCR followed using AccI-SalI sites and primers indicated in Table 7. 
 The Sec62-D1-2K-loop construct was generated by the insertion of D1-2K-loop 
construct between the EcoRI-NotI sites of human SEC62-containing plasmid [203] using 
PCR and the primers indicated in Table 7. 
 All constructs were confirmed by sequencing and the scheme of chimeras was 
summarized in Fig. 27B. 
5.2. Cell culture and transfection 
 HEK-293T and HeLa cells were grown in Dulbecco's Modified Eagle Medium 
(Gibco, Gaithersburg USA) supplemented with 10 % Fetal Bovine Serum (Gibco, 
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Gaithersburg USA, PAA Laboratories, Dartmouth USA) and 1 % penicillin-streptomycin 
(Sigma, St. Louis USA). Briefly, for transient transfection cells were suspended in 
trypsin-EDTA solution and split into 6-well plate (Greiner, Kremsmünster Austria) or 35 
mm diameter glass-bottom dish (MatTek, Ashland USA) at a concentration of 2×105 
cells/well. For luciferase promoter assay cells were plated into 24-well plate in 0.7×105 
cells/well concentration. Lipofectamine 2000 (Invitrogen) or Xtremegene HP (Roche, 
Basel Switzerland) reagents were used for cell transfection following the manufacturer’s 
instruction. 
5.3. Reagents and treatments 
 3,3′,5-triiodo-thyronine (T3) and thyroxine (T4) were purchase form Sigma Co. and 
dissolved in 40 mM NaOH, the appropriate concentration was determined by photometry. 
In treatments hormones were diluted in charcoal-stripped serum and used against NaOH 
vehicle. In brief, charcoal-stripped serum was generated as described in the following: 
100 mg charcoal (Sigma, St. Louis USA) and 50 mg dextran (Sigma, St. Louis USA) 
were preincubated overnight in 10 mM Tris buffer (pH=7.6). After centrifugation, 40 ml 
FBS were added to the pellet and incubated for 1 h on 45 °C. The suspension was 
centrifuged and the supernatant was added to DMEM in 1:10 dilution followed by 
membrane filtration. 
 Tetracycline (Sigma, St. Louis USA) was dissolved in MQ water and used in 1 
µg/ml as final concentration for 12-hours. 
 MG132 (Calbiochem, Darmstadt Germany) proteasome inhibitor was dissolved in 
dimethyl sulfoxide (DMSO, Sigma, St. Louis USA) and used in 2 µM final concentration 
for 4-hours against equivalent volume of DMSO as control. 
 Eeyarestatin I (Santa Cruz, Dallas USA) was dissolved in DMSO and used in 10 
μM as final concentration and applied for 4-hours against equivalent volume of DMSO 
as control. 
 Forskolin (Santa Cruz, Dallas USA) was dissolved in DMSO and applied in 20 nM 
as final concentration against equivalent volume of DMSO as control. 
 Treatments were carried out 48-hours after transfection. 
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5.4. Luciferase promoter assay 
 On the second day after transfection cells were washed with ice-cold 1× PBS and 
collected in 1× Passive Lysis Buffer (Promega, Madison USA). Luciferase assay was 
carried out by using Dual-Luciferase® Reporter Assay System (Promega, Madison USA) 
and Luminoskan Ascent equipment (Thermo, Waltham USA) following the 
manufacturer’s instructions. 
5.5. Quantitative PCR 
 Total RNA was isolated with the previously described TRIzol reagent for cell 
culture samples or with the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden Germany) for 
brown adipose tissue and nervous tissue samples. RNA was transcribed to cDNA with 
the High-Capacity cDNA Reverse Transcription Kit (Thermo, Waltham USA). RNA and 
cDNA concentrations were quantified using Qubit 2.0 fluorometric assay (Thermo, 
Waltham USA). TaqMan real-time PCR was applied for quantification of gene expression 
using TaqMan Fast Universal PCR Master Mix (Thermo, Waltham USA) and TaqMan 
Gene Expression Assays (Thermo, Waltham USA) listed below in Table 8. Reactions 
were run in ViiA™ 7 Real-Time PCR System (Thermo, Waltham USA). PCR data was 
normalized by the geometric mean of Gapdh and Hprt1 housekeeping genes [205] in case 
of mouse samples and by S18 in case of human cell lines. 
 Gene expression was calculated by 2-ΔΔCt method.  
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Table 8. List of TaqMan Gene Expression Assays used in this study 
species gene Assay ID 
mouse Adcyap1 Mm00437433_m1 
mouse Dio1 Mm00839358_m1 
mouse Dio2 Mm00515664_m1 
mouse Dio3 Mm00548953_s1 
mouse Slc16a2 Mm01232724_m1 
mouse Slco1c1 Mm00451845_m1 
mouse Thrb Mm00437044_m1 
mouse Tshb Mm03990915_g1 
mouse Trh Mm01963590_s1 
mouse March6 Mm00553784_m1 
mouse Wsb1 Mm01303073_m1 
mouse Usp33 Mm01316841_m1 
mouse Ucp1 Mm01244861_m1 
mouse Gapdh Mm99999915_g1 
mouse Hprt1 Mm01545399_m1 
human MARCH6 Hs00195391_m1 
human PTCH1 Hs00181117_m1 
human 18S Hs99999901_s1 
5.6. Western blot 
 Cells were harvested on the second day after transfection in Western lysis buffer 
containing 50 mM HEPES, 5 mM MgCl2, 1 mM EGTA, 100 mM NaCl, 1 % Triton X-
100, 0.1 mM dithiothreitol and supplemented with cOmplete™ Mini, EDTA-free 
protease inhibitor (Roche, Basel Switzerland). Protein concentration was determined by 
Bradford method and using Bio-Rad iMark Microplate Absorbance Reader. Samples 
were run in 4-20 % gradient (Bio-Rad) or 10 % acrylamide/bis-acrylamide gel. FLAG-
epitope was detected by M2 anti-FLAG monoclonal antibody (Sigma, St. Louis USA) 
using in 1:3000 dilution in 1× PBS and BM Chemiluminescence Western Blotting Kit 
(Roche, Basel Switzerland) following the manufacturers instruction. Western blots were 
imaged onto Kodak BioMax MS film (Sigma, St. Louis USA). 
5.7. Deiodinase assay 
 Tissue samples or cell pellets were obtained on the second day after transfection 
and sonicated in deiodinase assay buffer (100 mM potassium-phosphate, 1 mM EDTA, 
250 mM sucrose, 10 mM dithiothreitol, pH=7.0) on ice. 125I-labelled T4 (PerkinElmer, 
Waltham USA) was purified on the day of measurement on LH-20 Sephadex column (GE 
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Healthcare Life Sciences, New Jersey USA). Briefly, for D1 activity assay the following 
concentrations were used: 10 mM dithiothreitol, 100 000 CPM 125I-labelled T4 (Sigma, 
St. Louis USA), 1 µM T4 and cell total lysate in 300 µl as final reaction volume. For D2 
activity measurement the following concentrations were used: 20 mM dithiothreitol, 1 
mM 6-n-propyl-2-thiouracil (PTU), 100 nM T3, 100 000 CPM 
125I-labelled T4, 100 nM 
T4 and cell total lysate in 300 μl as final volume. Assay was terminated by the addition of 
200 µl normal horse serum (PAA Laboratories, Dartmouth USA) and 100 µl 
trichloroacetic acid (Sigma, St. Louis USA) on ice. Samples were centrifuged on 13,000 
rpm and supernatants were collected and measured using gamma counter (PerkinElmer, 
Waltham USA).  
 Deiodinase activities were calculated by Eq. 1. 
 
𝑨𝒄𝒕𝒊𝒗𝒊𝒕𝒚 =  
( 𝑪𝑷𝑴𝑺  −  𝑪𝑷𝑴𝑩 )
𝑪𝑷𝑴𝑻
∗ 𝒄𝑻𝟒  
𝟎. 𝟔 ∗  𝒕 ∗ 𝒎
 
Equation 1. 
where: 
CMPS: 125I counts of sample 
CPMB: 125I counts of background, non-transfected cells 
CPMT: 125I counts of tracer mix 
cT4: T4 concentration in reaction mix 
t: assay time 
m: amount of protein in the reaction from the sample  
 
 
5.8. Secreted alkaline phosphatase (SEAP) assay 
 Cells were cotransfected with the pSEAP2-Promoter plasmid containing the SV40 
early promoter (Clontech, Mountain View USA). Media were collected on day of cell 
treatment and stored on -20 °C until measurement. SEAP assay was performed using 
NovaBright Chemiluminescent SEAP Reporter Gene Assays (Thermo, Waltham USA) 
and Luminoskan Ascent equipment (Thermo, Waltham USA) according to the 
manufacturer’s instructions. 
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5.9. Fluorescent resonance energy transfer (FRET) 
 Cells were transfected as described above with the exception of plating into 35-mm 
glass-bottom dishes (MatTek, Ashland USA). Treatments and FRET measurements were 
performed on the second day after transfection using Nikon A1R laser scanning 
microscope equipped with Tokai Hit stage top incubator and Supertech temperature 
controller allowing the maintenance of constant 37 °C and 5 % CO2-level during imaging. 
Spectral detector was used for FRET measurement in virtual filter mode with the 
following parameters: 453 nm argon laser for ECFP excitation with 465-500 nm detection 
range; 514 nm argon laser for EYFP excitation with 515-540 nm detection range; 561 nm 
DPSS laser for excitation of mCherry with 600-650 nm detection range. Acceptor 
photobleaching method was applied, in case of 3-FRET experiments mCherry and EYFP 
were bleached sequentially in this order. Cells with at least 80 % bleach efficiency were 
involved into analysis. 
 Calculation of FRET efficiency was based on the increase of donor emission by the 
disruption of acceptor fluorophore using photobleaching and determined by Eq. 2 and 3. 
 FRET efficiency was normalized by the same value of fusion constructs of 
fluorophores (ECFP-EYFP and EYFP-mCherry) demonstrating the maximal achievable 
FRET. The background FRET signal caused by e.g. the oligomerization of fluorescent 
proteins was determined by the measurement of interaction between monomeric 
fluorescent proteins. The presence of interaction is defined by significant difference in 
FRET signal between investigated FRET pairs and the corresponding monomeric 
fluorescent proteins. 
 
 
𝑬𝑭𝑹𝑬𝑻(𝑬𝑪𝑭𝑷−𝑬𝒀𝑭𝑷) % = 
𝑬𝑪𝑭𝑷𝒑𝒐𝒔𝒕𝒃𝒍𝒆𝒂𝒄𝒉 − 𝑬𝑪𝑭𝑷𝒑𝒓𝒆𝒃𝒍𝒆𝒂𝒄𝒉
𝑬𝑪𝑭𝑷𝒑𝒓𝒆𝒃𝒍𝒆𝒂𝒄𝒉
 × 𝟏𝟎𝟎 Equation 2. 
 
 
𝑬𝑭𝑹𝑬𝑻(𝑬𝒀𝑭𝑷−𝒎𝑪𝒉𝒆𝒓𝒓𝒚) % = 
𝑬𝒀𝑭𝑷𝒑𝒐𝒔𝒕𝒃𝒍𝒆𝒂𝒄𝒉 −  𝑬𝒀𝑭𝑷𝒑𝒓𝒆𝒃𝒍𝒆𝒂𝒄𝒉
𝑬𝒀𝑭𝑷𝒑𝒓𝒆𝒃𝒍𝒆𝒂𝒄𝒉
 × 𝟏𝟎𝟎 Equation 3. 
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5.10. Animals and surgery 
 Animal experiments were performed in accordance with the legal requirements of 
the Animal Care and Use Committees of the Institute of Experimental Medicine 
(Hungarian Academy of Sciences, Budapest) following the European Communities 
Council Directive (2010/63/EU). 
 
5.10.1. Intracerebroventricular PACAP administration 
 Stereotaxic surgery was performed using Stereotaxic Instrument (David Kopf 
Instruments, Tujunga USA) to insert 26-gauge stainless-steel guide cannula (Plastics One, 
Roanoke USA) into the lateral ventricle of 8-week old male CD1 mice to the following 
coordinates: anteroposterior -0.2; lateral -1.0 and dorsoventral -2.0 from Bregma. 
Cannula was fixed by “Krazy Glue” (Electron Microscopy Sciences, Fort Washington 
USA). After one week recovery 33-gauge stainless-steel internal cannula was connected 
to the guide cannula and 300 pmol PACAP 1-38 in 2 μl artificial CSF (aCSF: 140 mM 
NaCl; 3.35 mM KCl; 1.15 mM MgCl2; 1.26 mM CaCl2; 1.2 mM Na2HPO4; 0.3 mM 
NaH2PO4; and 0.05 % BSA, pH 7.4) or 2 μl aCSF/BSA was injected into the lateral 
ventricle. Animals were sacrificed 4-hours after treatment by decapitation, blood and 
tissue samples were collected. Blood was centrifuged twice at 3000g at 4 °C and sera 
were stored at -80 °C. The mediobasal hypothalamus was dissected and the remaining 
parts of brain were frozen, cut to 1 mm thick coronal section, and the region of 
paraventricular nucleus was isolated using micropunch technique. The samples were 
stored at -80°C until further processing. 
 
5.10.2. Generation of hypo- and hyperthyroid mice 
 To generate hypothyroid animals 8-week-old CD1 mice were fed with iodide-
deficient chow and drinking water was supplemented with 0.1 % sodium perchlorate and 
0.5 % methimazole (Sigma, St. Louis USA) for 3 weeks. Hyperthyroid mice were 
generated by the following protocol: 10 mM T4 stock was prepared in 40 mM NaOH 
solution which was diluted in 0.002 % BSA-containing PBS to 75 μg/ml as final dilution. 
200 μl 75 μg/ml solution was injected i.p. for 3 days resulting 15 μg/day/animal dosage 
[206]. 
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5.11. Thyroid hormone measurement 
 Serum free T3 and T4 levels were measured using AccuLite CLIA microwells assays 
kit (Monobind, Lake Forest USA) with Luminoskan Ascent Luminometer and 
LIAISON® fT3 and fT4 assays with LIAISON® Analyzer following the manufacturer’s 
instructions. 
5.12. TSH bioactivity measurement 
 Chinese hamster ovary cells stably transfected with the human TSH receptor (CHO-
TSHR) was described in [207] and were plated 24-hours before the assay in 96-well plate 
in concentration of 5×104 cells/well. Cells were preincubated in 90 μl stimulation buffer 
(5 mM HEPES, 0.1 % BSA and 0.5 mM IBMX (Sigma, St. Louis USA) in 1× HBSS) for 
30 minutes. 10 μl serum samples were added to the cells and incubated for 1 hour 
followed by lysis in ethanol led to evaporate in 37 °C. Cells were collected in 50 μl Lysis 
buffer (5 mM HEPES, 0.1 % BSA and 0.3 % Tween-20 in MQ). Lysates were processed 
for cAMP measurement using AlphaScreen cAMP Assay Kit and EnSpire® Multimode 
Plate Reader (PerkinElmer, Waltham USA) following the manufacturer’s instructions. 
5.13. Immunohistochemistry 
 Mice were perfused transcardially with 40 ml 4 % paraformaldehyde dissolved in 
0.1 M PB. The brains were removed and postfixed for 2 hours following by cryoprotective 
immersion in 30 % sucrose in PBS overnight. 25 μm thick coronal sections were cut using 
freezing microtome (Leica Microsystems, Wetzlar Germany). Slices were permeabilized 
in 0.5 % Triton X-100 (Sigma, St. Louis USA) and 0.5 % H2O2 in PBS for 15 min and 
non-specific antibody binding was blocked by treatment in 2 % normal horse serum in 
PBS. Antibodies and sera were diluted in 2 % normal horse serum-containing PBS. 
Dilution and source of antibodies and sera are summarized in Table 9. The PAC1R 
antisera from Dr. Shioda was raised C-terminal intracellular domain while P8872 N-
terminal extracellular domain. The two antisera produced the same staining pattern (not 
shown). Imaging was performed using Nikon A1R laser scanning microscope. 
 
Table 9. List of antibodies and reagents used for immunohistochemistry 
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antigen 
primary 
antibody 
secondary 
antibody 
amplification fluorophore 
PAC1 
1:100 
rabbit anti-
PAC1 serum 
(from Dr. 
Shioda, Showa 
University) 
1:250 
biotin-
conjugated 
anti-rabbit 
IgG 
(Jackson) 
1:1000 
avidin-biotin 
complex 
(Vector Lab) 
biotinylated 
tyramide TSA 
amplification 
kit (Perkin 
Elmer) 
1:1000 
ABC 
streptavidin- 
fluorescein-
isothiocyanate 
(FITC) 
(Jackson) 
PAC1 
1:100 
rabbit anti-
PAC1 
antibody 
(Sigma) 
 
1:1000 
avidin-biotin 
complex 
(Vector Lab) 
biotinylated 
tyramide TSA 
amplification 
kit (Perkin 
Elmer) 
1:1000 
ABC 
streptavidin- 
fluorescein- 
isothiocyanate 
(FITC) 
(Jackson) 
vimentin 
1:1500 
goat anti-
vimentin 
antibody 
(Santa Cruz) 
1:500 
Alexa555-
conjugated 
IgG 
(Thermo) 
-  Alexa555 
GFAP 
1:500 
goat anti-
GFAP 
antibody 
(Santa Cruz) 
1:500 
Alexa555-
conjugated 
IgG 
(Thermo) 
-  Alexa555 
 
5.14. Statistical analysis 
 Prism 3.0 (GraphPad Software, La Jolla USA) and Statistica 8.0 (StatSoft, Tulsa 
USA) software’s were used for statistical analyzes. In brief, data were visualized as mean 
± SEM and for indication of significance level the following convention was used: *: 
p<0.05; **: p<0.01; ***: p<0.001. In general, two groups was compared by t-test, three 
or more samples were compared by the appropriate type of ANOVA and post hoc test. 
The applied statistical methods were specified in detail in the legends below figures.   
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6. RESULTS 
6.1. INTERACTION BETWEEN PACAP AND THYROID HORMONE SIGNALING 
6.1.1. PACAP induces D2 expression via cAMP/PKA pathway 
 Previous studies identified signaling pathways involved in the transcriptional 
control of D2 including cAMP/PKA, NF-κB and TTF1 [119, 149, 155] however upstream 
factors regulating D2 via these pathways are poorly characterized. The cAMP/PKA 
pathway is crucial in the thermal regulation of BAT and photoperiodic alterations of TH 
action in pineal gland, in both cases D2 is induced by adrenergic control. However the 
importance of cAMP/PKA pathway in tanycytes is poorly understood. Pituitary adenylate 
cyclase-activating polypeptide (PACAP) was identified as stimulatory factor of adenylate 
cyclase increasing intracellular cAMP production. Further studies revealed the broad 
range of biological action of PACAP and the hypothalamus is one of the major areas of 
PACAP-mediated processes e.g. control of energy balance, central thermoregulation and 
regulation of stress axis. Despite the remarkable overlap between PACAP action and TH-
mediated processes the interaction of this two major pathway is poorly understood. 
 The cAMP/PKA is one of the second messenger systems that is both activated by 
PACAP and was also reported to stimulate D2. This raised the question whether PACAP 
is able to act on DIO2 transcription. To test this hypothesis the effect of PACAP treatment 
on 7 kb 5’ flanking region (5’ FR) of human DIO2 gene was measured using dual 
luciferase promoter assay in HEK-293T cells found to express endogenous PACAP 
receptor PAC1R protein (Fig. 14A). 100 nM PACAP induced 7-fold increase of DIO2 
promoter activity (wtDIO2-Luc) after 4-hours and the induction was still detectable after 
24-hours (Fig. 14B). To test whether PACAP acts via cAMP/PKA pathway the cAMP 
response element (CRE) of 5’ FR of DIO2 gene was modified using site-directed 
mutagenesis to generate cAMP-insensitive DIO2 promoter region. The mutation is 
depicted on Fig. 14C. The effect and specificity of mutation was tested by the response 
to coexpression of PKA catalytic subunit α and NF-κB subunit p65. The CREmut-DIO2-
Luc construct lost its responsiveness to PKA but remained to be inducible by p65 (Fig. 
14D). 
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Figure 14. PACAP induces DIO2 promoter via cAMP/PKA pathway 
(A) PACAP receptor (PAC1R) is expressed in HEK-293T cells detected by Western blot. (B) Time-
dependent induction of DIO2 promoter activity by 100 nM PACAP 1-38 treatment (mean ± SEM, n=4 
per group). **: p<0.01, p<0.001 by one-way ANOVA followed by Newman-Keuls post hoc test vs 0h 
group; #: p<0.001 by t-test vs the wt-DIO2 promoter at the corresponding time-point. (C) Schematic draw 
of wild type (wt-DIO2) and cAMP response element mutant (CREmut-DIO2) DIO2 7 kb promoter 
luciferase reporter construct; mutations are indicated by lower case. (D) Responsiveness of CREmut-
DIO2 and wt-DIO2 promoter to the induction by PKA and p65 (mean ± SEM, n=3 per group). ***: 
p<0.001 by t-test vs non-induced (CMV) group. 
 
The CREmut-DIO2-Luc construct was found completely insensitive to treatment with 
100 nM PACAP indicating that PACAP-mediated upregulation of DIO2 5’ FR was 
carried out exclusively by cAMP/PKA pathway (Fig. 14B). 
 
6.1.2. Tanycytes express the PAC1R PACAP receptor 
 In order to identify cell types and brain regions where PACAP-mediated regulation 
of D2 could be relevant in vivo the expression of PAC1R is studied in D2-expressing 
cells. In the brain two major D2-expressing cell types are known; astrocytes and 
hypothalamic tanycytes. Immunohistochemistry was performed to test whether these cells 
express PAC1R protein. In vimentin positive tanycytes colocalization was observed 
between vimentin- and PAC1R-immunoreactivity in both of the α- and β-tanycytes 
subregion  
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Figure 15. PAC1R PACAP receptor is expressed in tanycytes of the mouse hypothalamus 
(A) Confocal images of dual immunofluorescence labeling of PAC1R (green) and vimentin (red) as 
tanycyte marker in the mouse mediobasal hypothalamus, open arrowheads indicate the colocalization of 
vimentin and PAC1R. (B) Higher magnification of median eminence region of panel A. (C) PAC1R 
(green) and the astrocyte marker GFAP (red) immunoreactivity did not colocalize in the mouse 
hippocampus. (D) Higher magnification from the region of dentate gyrus of panel C. (E) and (F) PAC1R 
(green) and astrocyte marker GFAP (red) immunoreactivity did not colocalize in the cortex. 
 
(Fig. 15A and B). In contrast, detectable PAC1R-staining was not observed in case of 
hippocampal and cortical GFAP-positive astrocytes (Fig. 15C and F). These results 
indicate tanycytes as cell-type where TH activation could be targeted by PACAP 
signalization. 
 
6.1.3. PACAP affects the feedback and development of HPT axis 
 Having identified PAC1R receptor expression in tanycytes asked whether PACAP 
affects local T3 generation and regulation of HPT axis in vivo. Therefore 300 pmol 
PACAP was injected intracerebroventrically into male CD1 mice and animals were 
sacrificed 4 hours after treatment. PACAP resulted 2.4-fold increase of D2 activity in the 
mediobasal hypothalamus where D2 is expressed exclusively in tanycytes indicating 
these cells have functional PACAP signalization (Fig. 16A). The response of TRH 
neurons to the increased TH activating capacity was tested by the measurement of Trh 
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expression in microdissected samples of the paraventricular nucleus using quantitative 
PCR. Trh mRNA level was decreased by 45.89 % compared to control mice (Fig. 16B). 
Tshb (encoding the β subunit of TSH) mRNA was suppressed by 23.30 % in pituitary 
(Fig. 16C) while Dio2 expression in this region was not changed by PACAP treatment 
(Fig. 16D). Serum TSH bioactivity and free T4 level were unaffected after 4-hours (Fig. 
16E and F) however that was expected taking into account the requirement of the series 
of transcriptional and secretory events in the HPT axis leading to alterations in TH 
synthesis and secretion and the long half-life of circulating T4. The D2 activities in cortex 
and hippocampus remained unaffected (Fig. 16G and H). 
 
 
 
Figure 16. PACAP induces D2 in tanycytes modulating HPT axis 
Effect of intracerebroventricular administration of 300 pmol PACAP 1-38 for 4-hour on (A) D2 activity 
in the mediobasal hypothalamus (B) Trh expression of the paraventricular nucleus (C) Tshb expression in 
the pituitary (D) Dio2 expression in the pituitary (E) serum TSH bioactivity (F) serum free T4 
concentration (G) D2 activity in the cortex (H) D2 activity in the hippocampus. Quantitative PCR data 
were normalized to the geometric mean of Gapdh and Hprt1 housekeeping genes and depicted as fold 
change compared to control group. (mean ± SEM, n=8 in PACAP-treated and n=9 in control group) *: 
p<0.05 by t-test. 
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 Acute PACAP treatment resulted remarkable changes in HPT axis therefore we also 
studied the long term effect of altered PACAP signalization on TH metabolism and the 
HPT axis using PACAP-deficient mice. Interestingly, these animals were found 
hypothyroid at the periphery showing decreased serum free T4 and T3 levels (Fig. 17A 
and B). TSH bioactivity was also decreased indicating alterations in the central regulation 
of HPT axis (Fig. 17C). As a consequence the hippocampal and cortical D2 activities 
were elevated compensating the decreased circulating TH availability (Fig. 17D and E). 
Regions where local T3 production has systemic importance via the modulation of HPT 
axis, in the mediobasal hypothalamus and pituitary the D2 activities were found to be 
unaffected (Fig. 17F and G). 
 
 
 
Figure 17. Thyroid hormone economy in adult PACAP-deficient (PACAP+/-) mice 
(A) Serum free T4 concentration (B) serum free T3 concentration (C) TSH bioactivity (D) D2 activity in 
the cortex (E) D2 activity in the hippocampus (F) D2 activity in the mediobasal hypothalamus (G) D2 
activity in the pituitary (H) serum inflammatory and antiinflammatory cytokine concentrations of wild-
type and PACAP-deficient mice (mean ± SEM, n=5 in PACAP+/+ and n=9 in PACAP+/-). n.d.: not 
detectable *: p<0.05; ***: p<0.001 by t-test. 
 
 
DOI:10.14753/SE.2016.1924
 53 
 Signs of central hypothyroidism of the observed phenotype were similar to the 
situation hallmarking non-thyroidal illness where infection results in suppressed HPT 
axis. Taking into account the important antiinflammatory effect of PACAP, the cytokine 
profile reflecting the immune status of PACAP-deficient animals was measured. 
Concentrations of IL-1α IL-1β IL-6, IL-10, CXCL1 and TNFα were not different between 
PACAP+/+ and PACAP+/- genotypes indicating that the affected HPT axis was not caused 
by a secondary process induced by altered immune state (Fig. 17H). 
 As demonstrated in Dio3 knock-out mice – that are hypothyroid despite the loss of 
the inactivating deiodinase – development of the HPT axis has a critical postnatal period 
when improper local T3 availability results in altered set point of the axis with 
consequences persisting also in adults. Therefore we speculated that the development of 
HPT axis could be the reason of the phenotype of the PACAP-deficient mice. To test this 
hypothesis the expression of genes involved in local TH metabolism and signalization 
were compared between 5-days old PACAP+/+ and PACAP+/- pups. Genes involved in 
measurement included activating and inactivating deiodinases: Dio2, Dio3; thyroid 
hormone transporters: Slco1c1 (Oatp1c1) and Slc16a2 (Mct8); thyroid hormone receptor 
β, Thrb and Trh. Importantly, Dio3 mRNA was increased in PACAP-deficient mice 
indicating increased TH inactivation resulting local hypothyroid conditions during the 
establishment of proper set point of the feedback of HPT axis (Fig. 18A). Other genes 
were found to be statistically unaffected. The peripheral TH availability was assessed by 
measuring hepatic Dio1 and Thrb expression well-established markers of thyroid status. 
Dio1 was found to be decreased while Thrb showed slight elevation indicating 
hypothyroid periphery (Fig. 18B). 
  
6.1.4. Thyroid hormones modulate Adcyap1 (PACAP) gene transcription 
 Having identified the PACAP as a novel central regulator of HPT axis we tested 
whether the PACAP-TH interaction is bidirectional therefore we investigated whether the 
THs are able to modulate PACAP synthesis. Therefore the modulatory effect of T3 was 
tested on 3 kb 5’ FR of mouse Adcyap1 gene in HEK-293T cells using dual luciferase 
reporter assay. 5’ FR of Adcyap1 gene was found to be insensitive for 0.1, 1, 10 and 100 
nM T3 treatment that the basal activity of the PACAP promoter is not 
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Figure 18. Regulation of local thyroid availability and action in 5-day old PACAP-deficient mice 
(A) Expression of genes involved in thyroid hormone metabolism (Dio2, Dio3), thyroid hormone transport 
(Slco1c1, Slc16a2), thyroid hormone receptor β (Thrb) and Trh. (B) Expression of Dio1 and Thrb in liver 
used to assess the peripheral thyroid hormone economy. Quantitative PCR data were normalized to the 
geometric mean of Gapdh and Hprt1 housekeeping genes and depicted as fold change compared to wild-
type (PACAP+/+) group (mean ± SEM, n=4 per genotype). *: p<0.05, **: p<0.01 by t-test. 
 
 
regulated directly by THs (Fig. 19A). It was previously shown that Adcyap1 transcription 
is upregulated by the cAMP/PKA second messenger system as demonstrated by the 
presence of catalytically active α subunit of PKA (Fig. 19B). Therefore we tested the 
effect of THs on the induction of 5’ FR of Adcyap1 by cAMP.  
 
 
 
Figure 19. Thyroid hormones interferes the cAMP/PKA-mediated activation of Adcyap1 (PACAP) 
promoter 
(A) Effect of 0.1, 1, 10 and 100 nM T3 for 1-, 3-, 5-hours on the promoter activity of the 3 kb 5’ FR of 
mouse Adcyap1 gene in HEK-293T cells (mean ± SEM, n=4 per group). (B) Induction of Adcyap1 gene 
promoter to constitutive active PKA signal (mean ± SEM, n=4 per group) ***: p<0.001 by t-test. (C) 
Effect of 100 nM T3 and mouse thyroid hormone receptor α (TRα) to the cAMP/PKA-mediated induction 
of the Adcyap1 promoter by 20 nM Forskolin (FSK) mean ± SEM, n=6 per group). A.U.: arbitrary unit 
(Firefly/Renilla luciferase) ***: p<0.001 by factorial ANOVA indicated interaction between T3, FSK 
treatment and presence of TRα and followed by Tukey post hoc test. 
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In the presence of TR and T3 the inductive effect of adenylate cyclase activator Forskolin 
(20 nM) was significantly decreased indicating that THs are able to antagonize the 
induction of Adcyap1 transcription by cAMP/PKA pathway (Fig. 19C). 
 To test the in vivo significance of THs in the regulation of PACAP synthesis hypo- 
and hyperthyroid mice were generated and expression of Adcyap1 gene was measured on 
microdissected regions with identified role in the hypothalamic regulation of energy 
homeostasis using quantitative PCR. Adcyap1 mRNA level was decreased in the 
parabrachial nucleus by hyperthyroid conditions (Fig. 20B), while in pituitary the 
Adcyap1 expression was decreased under hypothyroid conditions (Fig. 20H). However, 
in general, Adcyap1 transcription was not affected by altered TH level (Fig. 20). 
 
 
 
Figure 20. Adcyap1 gene expression in hypo-, eu- and hyperthyroid mice 
Expression of Adcyap1 gene in microdissected brain samples of hypo-, eu- and hyperthyroid mice. The 
qPCR data were normalized to the geometric mean of Gapdh and Hprt1 housekeeping genes and depicted 
as fold change compared to euthyroid levels (mean ± SEM, n>4 per group) *: p<0.05; **: p<0.01 and 
***: p<0.001 by one-way ANOVA followed by Newman-Keuls post hoc test vs euthyroid group. 
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6.2. CHARACTERIZATION OF MARCH6 AS D2 UBIQUITIN LIGASE 
6.2.1. Expression profile of March6 
 March6 was earlier shown to be coexpressed with D2 in tanycytes. First we aimed 
to identify extrahypothalamic target tissues where MARCH6 could be involved in the 
posttranslational control of TH activation via the ubiquitination of D2. Therefore the 
expression of the March6 gene was studied in different organs known to be important in 
D2-mediated T3 generation. Total mRNA was isolated from the cerebral cortex, pituitary, 
liver, kidney, muscle, heart, brown adipose tissue, and thyroid gland of Wistar rats and 
processed for semiquantitative RT-PCR. Intron-spanning primers were designed to detect 
March6, Wsb1 and Cyclophilin A as housekeeping gene. Strong March6 expression was 
detected in the cerebral cortex, pituitary, kidney, muscle and heart while lower level of 
March6 mRNA could be detected in the liver (Fig. 21). Wsb1, the substrate binding 
subunit of the firstly described ECSWSB1 D2 ubiquitin ligase was also expressed in the 
studied tissues. March6 mRNA was much less intense in the brown adipose tissue while 
Wsb1 showed solid expression in this tissue. Interestingly, March6 and Wsb1 transcripts 
could not be detected in the thyroid gland (Fig. 21). These data identified several tissues 
where MARCH6 could be potentially involved in the regulation of D2 e.g. the cerebral 
cortex, pituitary, muscle, heart where D2 is the exclusive or predominant activating 
deiodinase enzyme. It needs to be noted that other substrates targeted by MARCH6-
mediated ubiquitination are identified e.g. squalene monooxygenase (SM), 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase (HMGCR) involved in cholesterol biosynthesis 
[208, 209] and regulator of G protein signaling 2 (RGS2) stimulating the hydrolysis of 
GTP by Gα subunit of G-protein complexes [210] therefore the action of MARCH6 is not 
obviously restricted to D2 in these tissues. Additionally, MARCH6 has identified role as 
ERAD ubiquitin ligase thus beyond the posttranslational control of steroid biosynthesis, 
G-protein signaling and TH activation it also plays a crucial role in the quality control of 
protein translation.  
 
DOI:10.14753/SE.2016.1924
 57 
 
Figure 21. Expression of March6 and Wsb1 differ between rat tissues  
Results of semiquantitative RT-PCR on tissue samples from adult Wistar rats. Ppia (Peptidylprolyl 
isomerase A, Cyclophilin A) was used as housekeeping gene to control initial amount of RNA. 
 
6.2.2. Characterization of the human MARCH6 promoter 
 Having identified tissues where MARCH6 could be involved in the regulation of 
TH activation we aimed to study signaling pathways that could potentially modulate T3 
generation via the MARCH6-driven ubiquitination of D2. Since the promoter region of 
MARCH6 gene is poorly characterized we aimed to identify transcriptional factors that 
are involved in the regulation of MARCH6 expression. At first, potential transcription 
factor binding sites were predicted by in silico analysis of the 5’ flanking region (5’ FR) 
of human MARCH6 gene using TRANSFAC database (Biobase Gmbh., Germany). The 
5’ FR analysis focused mainly on the known regulators of TH metabolism and important 
modulators of development. In this manner potential NF-κB and CREB binding sites were 
identified. The core promoter of the MARCH6 gene contains GC-rich region several 
potential SP1 sites were located within the 130 bp-length region 5’ to the transcriptional 
start site (TSS). MARCH6 5’ FR was summarized on Fig. 22A. 
 To test the impact of these potential regulators on the transcription of MARCH6 
gene, first we cloned the 3.5 kb fragment of 5’ flanking region of the human MARCH6 
gene into pGL3-basic Firefly luciferase-expressing vector. The pGL3-MARCH6 
construct was used in dual luciferase assay allowing the measurement of promoter activity 
in presence of active transcriptional factors. This approach also allows the mutagenesis- 
or deletion-based characterization of regions with anticipated role in gene regulation. 
HEK-293T cells were used to coexpress promoter constructs with transcription factors. 
First the NF-κB and cAMP/CREB pathways were tested by overexpressing p65 and 
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protein kinase A catalytic subunit α (PKA), respectively. The 3.5 kb 5’ flanking region 
of MARCH6 gene was downregulated by both NF-κB and cAMP signals (Fig. 22B). 
 Additional experiments were performed to test the functional significance of the 
putative SP1 binding sites. For this purpose, the 130 bp-length region up from TSS 
containing the predicted SP1 sites was deleted. The truncation resulted a ~50 % decrease 
in the basal promoter activity demonstrating the functional role of SP1 sites in the 
regulation of MARCH6 transcription (Fig. 22C). 
 It is known that Sonic hedgehog (SHH) signaling antagonizes TH activation via 
stimulating the ubiquitination of D2 [161]. It was shown that expression of WSB1 subunit 
of the ECSWSB1 ubiquitin ligase of D2 is upregulated by the transcription factor Gli2, the 
main effector of SHH signalization. This mechanism allows a cross-talk between the two 
important morphological signals but it is not clarified whether the MARCH6 is also 
involved in the SHH-mediated downregulation of TH activating capacity. Therefore the 
transcriptional regulation of the 3.5 kb 5’ flanking region of MARCH6 gene upon SHH 
induction was tested. Experiments were performed in HeLa cells which were previously 
shown to be more appropriate to study of SHH-related effects. To mimic the SHH signal 
expression plasmid containing the N-terminal truncated constitutive active fragment of 
Gli2 (Gli2-ΔN2) transcription factor was cotransfected with the pGL3-MARCH6 reporter 
construct. While the Gli2 reporter positive control (8×Gli-BS) and WSB1 promoter were 
induced in this experimental setup MARCH6 was not upregulated (Fig. 22D). 
 This finding was also supported by measuring the alterations of endogenous 
MARCH6 mRNA. HeLa cells were transfected with Gli2-ΔN2 or empty expression vector 
and processed for TaqMan real-time PCR measuring. The MARCH6 mRNA level was 
not changed in the presence of active SHH-signalization while the PTCH1expression – 
used as positive control for active SHH-signalization – was readily induced (Fig. 22E). 
 The Wnt signalization is also a fundamental regulator of development. However, in 
contrast to the SHH pathway which acts in the determination of ventral structures, Wnt is 
expressed in the dorsal part of developing neural tube. To address the question whether 
this important morphogenic signal could affect the TH metabolism via MARCH6 the 
effect of β-catenin the transcriptional coregulator of Wnt signalization was tested on 
MARCH6 5’ FR. The MARCH6 promoter region was showed 3-fold suppression by β-
catenin (Fig. 22B). 
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 In conclusion, these data indicate the opposite regulation of DIO2 and MARCH6 by 
PKA and NF-κB signaling pathways and revealed an important difference between the 
two ubiquitin ligases of D2: while the WSB1 is a positive target the SHH signaling 
pathway, MARCH6 remains to be unaffected and regulated independently. Therefore the 
ubiquitin-conjugating machinery could serve as an integrator of different signals involved 
in the downregulation of TH activating capacity. 
 
 
Figure 22. Transcriptional regulation of the human MARCH6 gene. 
(A) Schematic depiction of the structure and predicted binding sites of the 3.5 kb 5’ FR of human 
MARCH6 gene. (B) Responsiveness of the 3.5 kb 5’ FR of human MARCH6 gene for NF-κB (p65), PKA, 
SHH (Gli2); Wnt (β-catenin) pathways using dual luciferase assay (mean ± SEM, n≥5 per group). (C) 
Impact of SP1 sites on the basal promoter activity of the 3.5 kb 5’ FR of human MARCH6 gene as assessed 
by deletion of the 130 bp-length region proximal to the transcriptional start site (MARCH6-Δ130) (mean 
± SEM, n=3 per group). (D) Assessment of SHH-mediated (Gli2) regulation of MARCH6 and WSB1 
promoters with by dual luciferase assay. An 8×Gli-BS constructs was used as positive control containing 
an octamer of canonical Gli-binding sites 5’ to the luciferase coding region (mean ± SEM, n≥5 per group). 
(E) SHH-responsiveness of the endogenous human MARCH6 in HeLa cells tested by qPCR, PTCH1 was 
used as control for the cotransfected Gli2 encoding plasmid; data were normalized by 18S ribosomal RNA 
housekeeping gene and depicted as fold change compared to control transfected with empty CMV vector 
(mean ± SEM, n=3 per group). *: p<0.05, **: p<0.01, ***: p<0.001 by t-test vs control or non-induced 
group expressing empty vector (CMV). 
6.2.3. Contribution of ubiquitination to the regulation of D2 in brown adipose 
tissue (BAT) 
 In BAT, adrenergic stimuli act via β3-adrenergic receptor activating cAMP 
production that transcriptionally induces Dio2 expression. Our in vitro data suggested that 
the activity of the March6 promoter is downregulated by the cAMP/PKA pathway. This 
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prompted us to study whether the upregulation of T3 generation in the cold induced BAT 
could be also affected by a novel posttranslational mechanism based on cAMP/PKA 
mediated decrease of D2 ubiquitination. To test this hypothesis we measured in the BAT 
the expressional response of D2 ubiquitination associated genes to cold stress, a condition 
known to evoke cAMP generation via adrenergic signaling. 
  In the first set of experiments mice were transferred from thermoneutral 
temperature (30 °C) to 4 °C for 1, 2, 4, 6 or 9 hours. Samples from interscapular BAT 
were processed for qPCR and D2 activity measurements. March6 expression was not 
affected in BAT by cold stress (Fig. 23A). Interestingly, Wsb1, the substrate recognition 
subunit of the ECSWSB1 complex showed elevated mRNA level from the first hour of cold 
stress during the whole period of experiment (Fig. 23B). Usp33 deubiquitinase  
 
 
Figure 23. Expression of genes involved in ubiquitin-mediated regulation of D2 in cold induced BAT 
of CD1 mice 
Expression of (A) March6 (B) Wsb1 ubiquitin ligases and (C) Usp33 deubiquitinase (D) Dio2 mRNA 
level and D2 activity (E) Ucp1 expression. The qPCR data were normalized to the geometric mean of 
Gapdh and Hprt1 housekeeping genes and gene expression was depicted as fold change compared to 
group kept on thermoneutrality at 30°C (0h group) (mean ± SEM, n=4 per group). *: p<0.05, **: p<0.01, 
***: p<0.001 by one-way ANOVA followed by Newman-Keuls post hoc test vs 0-hour group. 
expression was induced 2-hours after the transfer of mice to 4 °C (Fig. 23C). Dio2 mRNA 
level was increased after 1h at 4 °C while elevated D2 activity could be measured after 
4-hours of cold stress (Fig. 23D). The uncoupling protein 1 (Ucp1) mRNA was found to 
be elevated from 4-hours after the start of the cold stress (Fig. 23E). 
 To test whether the ubiquitin-mediated regulation could be involved in the 
reduction of elevated T3-activating capacity under cold induction, we performed reversed 
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experimental design transferring mice kept at 4 °C for 8-hours to the thermoneutral 30 °C 
where non-shivering thermogenesis is absent in rodents. Mice were sacrificed 1, 2, 4, 6 
or 8 hours after the end of cold stress and processed for the similar measurements as 
described above. Similarly to the previous experiment March6 expression was not 
affected by the induced state of BAT (Fig. 24A). Wsb1 expression was also showed 
similar pattern and found to be highly sensitive for adrenergic activation of the BAT and 
its mRNA level returned to the non-induced level after the transfer of animals to 30 °C 
(Fig. 24B). Usp33 deubiquitinase showed elevated mRNA level with slow decrease 
during the whole period after the end of cold stress (Fig. 24C).  
 
Figure 24. Expression of genes involved in ubiquitin-mediated regulation of D2 in BAT after 8-
hours cold stress of CD1 mice 
Expression of (A) March6 (B) Wsb1 ubiquitin ligases and (C) Usp33 deubiquitinase (D) Dio2 mRNA 
level and D2 activity (E) Ucp1 expression. The qPCR data were normalized to the geometric mean of 
Gapdh and Hprt1 housekeeping genes and gene expression was depicted as fold change compared to 
group kept on thermoneutral temperature at 30 °C (-8h group) (mean ± SEM, n=3 per group). *: p<0.05, 
**: p<0.01, ***: p<0.001 by one-way ANOVA followed by Newman-Keuls post hoc test vs group kept 
on thermoneutral temperature (-8h group); #: p<0.05, ###: p<0.001 by one-way ANOVA followed by 
Newman-Keuls post hoc test vs 0-hour group. 
Dio2 mRNA was elevated for 2-hours after the end of cold stimulus compared to the 
control group kept constantly at 30 °C however showed a remarkably rapid decrease after 
the first hour at 30 °C. In contrast after 6-hours of the transfer from 4 °C the D2 activity 
was still elevated and decrease could be detected only at 6-hours compared to the induced 
state (Fig. 24D). Ucp1 mRNA level was found to be stable and its expression was not 
decreased even after 6-hours at 30 °C (Fig. 24E). 
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6.2.4. Topology of D2-MARCH6 interaction 
 Previously Doa10 the yeast orthologue of MARCH6 ubiquitin ligase was identified 
by yeast-two hybrid screen as a potential interaction partner for D2. Other studies 
demonstrated that silencing of MARCH6 led to increased stability of D2 protein in 
mammalian cells indicating that MARCH6 is involved in the regulation of D2 enzyme. 
However, crucial pre-requisites of a functional ubiquitin D2 ligase remained to be 
established, i.e. the protein-protein interaction between D2 and MARCH6 and the 
interacting domains remained to be determined. 
 To address this question we performed fluorescent resonance energy transfer 
(FRET) studies. ECFP-EYFP FRET pairs were used in the acceptor photobleaching 
method to detect FRET signal. The EYFP-MARCH6 and MARCH6-EYFP (EYFP on the 
N- or C-terminus of MARCH6, respectively) constructs were generated by standard 
recombinant DNA techniques. The interactions were measured between these proteins 
and ECFP-tagged D2 either on its N- or C-terminus in living HEK-293T cells. The exact 
membrane topology of the Doa10/MARCH6 protein was unresolved and the localization 
of its C-terminus was controversial. Therefore we investigated both possibilities whether 
i) the C-terminus of MARCH6 is localized in the cytosol allowing the interaction with 
the C-terminus of D2 or ii) expressed in the ER lumen providing access for the N-terminus 
of D2 (Fig. 25A). 
 Measurable FRET signal was detected between the cytosolic C-terminus of D2 and 
the N-terminus of MARCH6 (D2-ECFP vs EYFP-MARCH6; EFRET = 20.04 ± 1.02 %) 
that was significantly different from the same value of monomeric fluorescent proteins 
(ECFP and EYFP) used for detection of non-specific background (8.03 ± 2.87 %) (Fig. 
25B). In contrast, FRET signal could not be detected between the C-terminus  
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Figure 25. N-terminus of MARCH6 interacts with D2 on T4-dependent manner  
(A) Design of FRET pairs used to reveal and map the topology of MARCH6 and D2 interaction, the C-
terminus of MARCH6 was measured in pair with both the C- and N-terminus of D2. (B) Results of FRET 
measurement of protein-protein interactions in HEK-293T cells, data are expressed as percentage of 
ECFP-EYFP tandem (C-Y) used as positive control while monomers of ECFP and EYFP (C Y) were 
applied to detect non-specific background. The order of C (ECFP) or Y (EYFP) in the name of constructs 
reflects the type of fusion (mean ± SEM, n≥15 per group) **: p<0.01, ***: p<0.001 by one-way ANOVA 
followed by Tukey post hoc test vs monomer. (C) Photomicrographs of HEK-293T cells demonstrating 
the acceptor photobleaching method used for detection of MARCH6 and D2 interactions. Left-top: 
prebleach (pre)acceptor; right-top: postbleach (post) acceptor; left-bottom: prebleach donor; right-bottom: 
postbleach donor. (D) Results of dual luciferase assay demonstrating that the promoter activity 3.5 kb 5’ 
FR of human MARCH6 gene is not regulated by 100 nM T3. (E) Effect of 10 μM T4 on MARCH6-D2 
interaction. D2 homodimers were used as positive control of treatment (mean ± SEM, n≥15 per group). 
**: p<0.01, ***: p<0.001 by t-test. 
 
of MARCH6 and either the cytosolic C-terminus of D2 (MARCH6-EYFP vs D2-ECFP; 
EFRET = 4.26 ± 1.38 %) or the ER-lumen localized N-terminus of D2 (MARCH6-EYFP 
vs ECFP- D2; EFRET = 0.73 ± 1.11 %) (Fig. 25B). These data suggest that the structural 
properties responsible for the recognition of D2 as substrate are localized in close 
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proximity to the N-terminus of MARCH6 protein. Moreover this FRET study directly 
proved the existence of protein-protein interaction between MARCH6 and D2 in living 
cell and identified MARCH6 as functional ubiquitin ligase of D2. 
 
6.2.5. Thyroid hormone-dependence of MARCH6-mediated regulation of D2 
 First, the involvement of THs in the regulation of MARCH6 action was investigated 
on transcriptional level using a dual luciferase promoter assay as described above. 
Therefore the response of 5’ FR of human MARCH6 gene was measured by 100 nM T3 
treatment for 4-hours. These data demonstrate that MARCH6 expression is not regulated 
by THs at transcriptional level (Fig. 25D). 
 However, THs regulates D2 activity most effectively via increasing its 
ubiquitination directly. This mechanism is governed by the D2 substrate, T4, and not 
subjected to the more typical product driven (i.e. T3-mediated) regulation. However it was 
not clarified whether the MARCH6 – similarly to WSB1 – is involved in this regulatory 
process. FRET studies were applied to target this question. HEK-293T cells were 
transfected with the previously described constructs and on the second day after 
transfection and treated with 10 µM T4 in charcoal-stripped serum for 4-hours. The FRET 
signal between the N-terminus of MARCH6 and C-terminus of D2 (EYFP-MARCH6 vs 
D2-ECFP) was significantly increased by 39.17 % upon T4-treatment (Fig. 25E). In 
contrast, measurable FRET signal still could not been detected between the C-terminus 
of MARCH6 and C-terminus of D2 (MARCH6-EYFP vs D2-ECFP) in presence of T4. 
The D2-D2 homodimer (D2-ECFP vs D2-EYFP) used as positive control of treatment 
showed a 29.41 % decrease in FRET signal (Fig. 25E). These data demonstrate the 
involvement of MARCH6 in the substrate-induced downregulation of TH activation via 
the ubiquitination of D2. 
 
6.2.6. Construction of a 3-FRET approach to study parallel the interactions of 
D2 with the two E3-ligases  
 FRET experiments proved the direct protein-protein interaction of MARCH6 with 
D2 during D2 ubiquitination and revealed the involvement of MARCH6 in the substrate-
mediated inactivation of D2 by ubiquitination. However, it was not known whether 
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MARCH6 cooperates or competes with WSB1 – the substrate-recognition subunit of the 
other described ubiquitin ligase of D2 – whether both of them are coexpressed with D2 
as the case in hypothalamic tanycytes. Therefore we established a 3-FRET approach 
based on the combination ECFP-EYFP and EYFP-mCherry FRET-pairs within one 
system. Based on their properties the EYFP could be both a FRET acceptor for ECFP and 
at the same time representing a donor for mCherry. To achieve this, the following 
constructs were generated: ECFP was fused to the N-terminus of MARCH6 (ECFP-
MARCH6) and mCherry was added to the C-terminus of WSB1 followed by additional 
SOCS-box cassette (WSB1-mCherry) (Fig. 26A). These constructs were used in 
combination with the previously described D2-EYFP allowing the parallel detection of 
D2-MARCH6 and D2-WSB1 interactions within living cells (Fig. 26B). Using this 3-
FRET system allowed the investigation of ligase preference of the T4-mediated 
ubiquitination.10 µM T4-treatment resulted in 55.55 % increase of D2-MARCH6 and 
49.99 % increase of D2-WSB1 FRET signal interaction demonstrating that the T4-
mediated ubiquitination is carried out by both ubiquitin ligases at a very similar level 
(Fig. 26C). 
 
 
Figure 26. 3-FRET assisted detection of the interaction between D2 and MARCH6 and WSB1 
ligases 
(A) Schematic depiction of the 3-FRET system. (B) Flowchart of detection based on sequential bleaching 
of FRET donors. In the first cycle mCherry was bleached and EYFP intensity measured followed by the 
bleaching of EYFP and measuring ECFP intensity. (C) Effect of 10 μM T4 on the protein-protein 
interactions between D2 and ligases. Data are expressed as percentage of ECFP-EYFP or EYP-mCherry 
tandem (mean ± SEM, n≥25). **: p<0.01, ***: p<0.001 by t-test. 
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6.3. STRUCTURAL BACKGROUND OF THE UBIQUITINATION OF DEIODINASES 
6.3.1. Molecular background of stability and ubiquitination of deiodinases 
 Previous studies identified critical structural elements and properties involved in 
the control of D2 activity by the ubiquitin-proteasome system. However the minimal 
requirements of a deiodinase protein sufficient to be processed by ubiquitination are 
unresolved. To address this question we constructed D1-D2 chimeras using the stable, 
non-ubiquitinated D1 protein as backbone and inserted ubiquitination-related D2 
structural elements into original D1 sequence resulted in chimeric deiodinase proteins. 
The following D2-specific properties were investigated: the ubiquitin chain carrier lysines 
(K237 and K244 in human D2 protein), instability-loop (aa. 92-97 in human D2) and ER-
localization. Structural elements were inserted into the homologue regions of rat D1: 
arginine was changed to lysine at position 223 and proline was mutated to lysine at 
position 230. The instability-loop (-TEGGDN- sequence in human D2) was inserted 
between amino acids 102 and 103 (Fig. 27A). ER localization was carried out by N-
terminal SEC62 fusion. These mutations were combined to reveal their importance in the 
ubiquitination of deiodinases. Therefore the following chimeras were constructed and the 
abbreviations used in the text were indicated in parenthesis: P230K (D1-K); R223K and 
P230K (D1-2K); instability-loop- and P230K-containing (D1-K-loop); instability-loop-, 
R223K- and P230K-containing (D1-2K-loop); SEC62-fusion, instability-loop-, R223K- 
and P230K-containing (SEC62-D1-2K-loop). Structures of chimeras were depicted on 
Fig. 27B. Constructs were cloned into the mammalian Tet-off D10 expression system 
allowing the capability of tetracycline-mediated selective suppression of recombinant 
protein expression. 
 A subset of these chimeras were fused to the N-terminus of EYFP allowing protein-
protein interaction studies to reveal the importance of these properties in the recognition 
of D2 by its ubiquitin ligases. 
 The chimeras were expressed in HEK-293T cells and their stability and 
susceptibility to ubiquitination were studied by Western blot. To assess the half-life of 
chimeric deiodinases their transcription was stopped by tetracycline in 1 µg/ml as final 
concentration for 12-hours using a Tet-repressible promoter system (Fig. 28A). In case 
of the lysine-containing chimeras (D1-K and D1-2K) no high molecular mass  
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Figure 27. Design of D1-D2 chimeras 
(A) Alignment of D1 and D2 proteins of different species. Amino acid positions were indicated according 
to the homologue positions in human D2. Specific elements of D2 involved in ubiquitination are boxed 
and indicated by arrows. (B) Schematic drawing about the constructed chimeric D1-D2 proteins applied 
in the study. All constructs are tagged with FLAG-epitope and selenocysteine was mutated to cysteine in 
order to avoid the requirement of selenocysteine incorporating apparatus. 
 
ubiquitinated forms were present and the stability was not affected compared to wild-type 
D1 (Fig. 28B). Insertion of the instability-loop of D2 to the lysine-containing chimera 
(D1-K-loop and D1-2K-loop) remarkably reduced the stability of the proteins although 
high molecular mass ubiquitinated forms could not been revealed by Western blot (Fig. 
28B). A lysine- and loop-containing chimera was directed into the ER (SEC62-D1-2K-
loop) to test the protein in the compartment where the wild-type D2 is located. In this 
case a shorter half-life and high molecular mass forms could be observed indicating this 
mutant undergoes ubiquitination (Fig. 28B). 
 Ubiquitination of chimeras was also tested by an independent approach based on 
the inhibition of the proteasome. Loss of the catalytic activity of the proteasome impacts 
UPS-targeted substrate proteins in two ways. As a direct consequence the degradation of 
these proteins is blocked and due increased half-life this leads to elevated biological 
DOI:10.14753/SE.2016.1924
 68 
activity of proteins that remain in active form after ubiquitin conjugation. As an indirect 
effect on protein turnover the impaired processing of ubiquitinated proteins results in 
blocked recycling of ubiquitin originating from the ubiquitin chain on these proteins that 
leads to ubiquitin-depletion within the cell that consequently interferences with ubiquitin-
conjugation. Therefore transfected cells were treated by 2 µM MG132 a commonly used 
proteasome inhibitor and the deiodinase activity of cell lysates was measured (Fig. 28A). 
 
 
 
Figure 28. Assessment of the stability and ubiquitination of D1-D2 chimeras 
(A) Experimental design. (B) Testing the stability and ubiquitination of chimeras by Western blot. HEK-
293T cells expressing chimeras were treated by 1 mg/l tetracycline for 12 hours to selectively abort de 
novo synthesis and samples were run in 4-20% gradient gel followed by the detection using FLAG-tag. 
Open arrow indicates the high molecular mass ubiquitinated deiodinase forms, asterisk indicates the 
SEC62-D1-2K-loop construct run in 10% gel and detected by shorter exposure. (C) Testing the 
ubiquitination of chimeras by 2 μM MG132 proteasome inhibitor treatment for 4-hours. D1 activities were 
normalized by cotransfected secreted alkaline phosphatase (SEAP). Data represented as fold change of 
MG132/DMSO vehicle. D2 was used as positive control of MG132 treatment (mean ± SEM, n=3). *: 
p<0.05 by t-test. 
 
 
The activities of the lysine- and loop-containing chimeras were not increased by the 
inhibition of proteasome supporting the results of stability studies that these mutants are 
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not targeted by ubiquitin-mediated regulation (Fig. 28C). The ER directed mutants could 
not be tested this way due to the known loss of enzymatic activity by the fusion to SEC62. 
 
6.3.2. Importance of D2-specific elements in the recognition by ubiquitin ligases 
 Protein-protein interactions were measured to exclude aspecific ubiquitination of 
the chimeras and test the structural basis of the recognition of D2 as substrate for its 
ubiquitin ligases. Therefore FRET experiments were performed using C-terminal EYFP-
tagged chimeras containing lysines and loop-region (D1-2K-loop-EYFP), directed to ER 
(SEC62-D1-EYFP) and containing these properties together (SEC62-D1-2K-loop-
EYFP) combined with ECFP-tagged WSB1 (WSB1-ECFP) or MARCH6 (ECFP-
MARCH6). Measurable FRET signal was not observed either for the lysine- and loop-
containing (D1-2K-loop-EYFP) or the ER-localized (SEC62-D1-EYFP) mutants 
indicating these chimeras could not been recognized by the WSB1 or MARCH6 proteins 
(Fig. 29A and B). 
However intense FRET signal (EFRET = 53.14 ± 2.5 %) could be detected between the 
lysine- and loop-containing ER-targeted chimera (SEC62-D1-2K-loop-EYFP) and 
WSB1 demonstrating these elements in combination allow the recognition by one of the 
known D2 ligases (Fig. 29A and B). Interestingly, this chimera did not interact with 
MARCH6 suggesting different structural background of the recognition of D2 by its 
ubiquitin ligases (Fig. 29A and C). Our data also demonstrate that the ubiquitination of 
SEC62-D1-2K-loop chimera is carried out by one of the ubiquitin ligases of D2 the 
ECSWSB1 complex. 
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Figure 29. Processing of chimeric D1-D2 chimeric proteins by the ubiquitin-proteasome system 
(A) Importance of D2-specific elements in the recognition by ubiquitin ligases assessed by FRET in HEK-
293T cells. Data are expressed as percentage of ECFP-EYFP tandem (C-Y) used as positive control while 
monomer ECFP and EYFP (C Y) were applied to detect non-specific background (mean ± SEM, n≥30 
per group). ***: p<0.001 by one-way ANOVA followed by Tukey post hoc test vs monomer (B) 
Photomicrograph Photomicrography of individual HEK-293T cells demonstrating FRET between 
deiodinase chimeras and WSB1. (C) Same as C with MARCH6. Each panel contains the following 
pictures: left-top: prebleach (pre) acceptor; right-top: postbleach (post) acceptor; left-bottom: prebleach 
donor; right-bottom: postbleach donor. The order of the fluorescent protein (C or Y) and the tagged protein 
in the name of the constructs reflects their position in the fusion protein. 
 
6.3.3. Effect of threonine/alanine polymorphism in D2 on the interaction with 
ubiquitin ligases 
 The threonine/alanine polymorphism in the position of 92th amino acid of human 
D2 was suggested to affect glucose metabolism and HPT axis therefore the polymorphism 
of D2 could have importance in diabetes and diseases associated with impaired TH 
metabolism. Despite the clinical data suggesting elevated insulin level, increased risk of 
type 2 diabetes, osteoarthritis and mental deficits in polymorphic DIO2 allele carriers the 
impact of the polymorphism on the properties of D2 protein has not been adequately 
resolved. Taking into account that this amino acid position belongs to the D2-specific 
loop-region involved in the inherent instability of D2 protein the mutation of threonine to 
alanine could potentially affect D2 degradation via ubiquitination. Therefore using the 
previously established 3-FRET approach we studied whether the amino acid change 
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affects the recognition of D2 by its ubiquitin-conjugating apparatus. FRET signal was 
similar in case of interaction with WSB1 and allele variants of D2: EFRET(WSB1-D2-92T) 
= 44.60 ± 4.84 % and EFRET(WSB1-D2-92A) = 42.29 ± 4.95 % (Fig. 30). The induction 
of D2-WSB1 interaction by 10 μM T4 treatment was also unaffected in case of allele 
variants: EFRET(WSB1-D2-92T●T4) = 68.86 ± 7.82 % and EFRET(WSB1-D2-92A●T4) = 
68.64 ± 9.03 % resulting 54.38 % increase for D2-92T and 62.31 % for D2-92A (Fig. 
30). Interestingly, the T4-induction of D2-MARCH6 interaction was slightly altered by 
the substitution of 92th threonine to alanine. While the basal interaction was similar on 
wild-type and polymorphic D2 EFRET(MARCH6-D2-92T) = 24.39 ± 2.57 % and 
EFRET(MARCH6-D2-92A) = 29.33 ± 3.32 % the T4 treatment did not resulted significant 
increase of D2-MARCH6 interaction in case of D2-92A allele: EFRET(MARCH6-D2-
92T●T4) = 37.43 ± 3.68 % EFRET(MARCH6-D2-92A●T4) = 36.43 ± 3.22 % resulting 
53.44 % induction for D2-92T while for D2-92A that was not statistically significant 
indicating that posttranslational regulation could be affected by the common 
polymorphism of D2 (Fig. 30). 
 
Figure 30. Effect of the T92A D2 polymorphism on the recognition of D2 by ubiquitin ligases  
FRET efficiencies between the wild-type (D2-Thr92) and polymorphic (D2-Ala92) D2 assessed by 3-
FRET. Data are expressed as percentage of ECFP-EYFP or EYFP-mCherry tandem (mean ± SEM, n≥25). 
*: p<0.05 by two-way factorial ANOVA followed by Newman-Keuls post hoc test. 
 
6.3.4. Relationship between deubiquitination and extraction of D2 from the ER 
 D2 is a type I transmembrane protein and is processed by the endoplasmic reticulum 
associated degradation (ERAD) [211]. As a consequence D2 needs to be extracted from 
the ER membrane to reach the cytosolic proteasome. This process is carried out by the 
p97/VCP complex. However the inhibition of this machinery by Eeyarestatin I (EERI) 
did not result an increase in D2 activity. To target this question, we used FRET to measure 
protein-protein interactions between the D2-D2 homodimers and between the D2 and its 
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deubiquitinase enzyme the USP33. D2-EYFP/D2-ECFP or ECFP-USP33/D2-EYFP 
fusion constructs were expressed in HEK-293T cells which were treated by 10 µM EERI 
and/or 10 µM T4. The FRET signal between the globular domains of D2-D2 homodimers 
was significantly decreased by 30.30 % compared to the absence of T4 (Fig. 31A). 
Presence of 10 µM EERI alone resulted in decreased interaction between monomers of 
D2-D2 homodimers and the rate of reduction was similar to that achieved with T4-
treatment (Fig. 31A). Interestingly, the addition of 10 µM T4 beside EERI did not result 
in further decrease in the interaction between the globular domains of D2 (Fig. 31A). 
 These findings suggested an impaired deubiquitination capacity and as a 
consequence the enrichment of the inactive ubiquitinated D2. To target this proposed 
mechanism the alterations of interaction between the D2 and USP33 was measured. 
Inhibition of D2 export by EERI treatment significantly reduced the FRET signal between 
D2 and USP33 by 51.89 % (Fig. 31B). This effect was independent of D2 substrate since 
in presence of 10 µM T4 the EERI-driven decrease was very similar, 52.20 % (Fig. 31B). 
In contrast the inhibition of proteasomal activity by 1 µM MG132 resulting the ablation 
of the final processing of ubiquitinated D2 did not result detectable alteration in the D2-
USP33 interaction (Fig. 31B). 
 
 
Figure 31. Inhibition of p97/VCP complex affects the deubiquitination of D2 
(A) Interaction between globular domains of a D2 homodimer in the presence of p97/VCP inhibitor 10 
μM Eeyarestatin I (EERI) and/or 10 μM T4. Data are represented as percentage of ECFP-EYFP tandem 
(mean ± SEM, n≥40). ***: p<0.001 by two-way factorial ANOVA followed by Tukey post hoc test. (B) 
Interaction between globular domain of D2 and USP33 deubiquitinase in presence of 10 μM Eeyarestatin 
I (EERI) or 2 μM MG132 proteasome inhibitor in combination with 10 μM T4 (mean ± SEM, n≥20). ***: 
p<0.001 by two-way factorial ANOVA followed by Tukey post hoc test revealing effect of drugs and T4 
without interaction. 
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7. DISCUSSION 
7.1. INTERACTION BETWEEN PACAP AND THYROID HORMONE SIGNALING 
7.1.1. PACAP induces D2 expression via cAMP/PKA pathway 
 The inductive effect of PACAP on the 5’ FR of human DIO2 gene was 
demonstrated in HEK-293T cells showed endogenous PAC1R receptor expression. 
Importantly, PAC1R – in contrast with the other group of PACAP receptors including 
VPAC1 and VPAC2 – is selective for PACAP over vasoactive intestinal polypeptide 
(VIP). PACAP action via PAC1R receptor is transmitted by two major intracellular 
signalization cascades: the cAMP/PKA and PLC/Ca2+. To dissect between intracellular 
pathways involved in the induction DIO2 by PACAP, cAMP response element (CRE) 
mutant 5’ FR of DIO2 was generated. The efficiency and specificity of mutation was 
demonstrated by its unresponsiveness to PKA overexpression and retained activation by 
a well-documented positive regulator of D2, the NF-κB cascade mimicked by p65 
coexpression [155]. The induction of DIO2 promoter by PACAP was completely 
abolished by the mutation of CRE suggesting that PACAP action on DIO2 promoter is 
carried out exclusively by the cAMP/PKA second messenger system. Transcriptional 
regulation of DIO2 includes several identified intracellular signals however the upstream 
factors activating these cascades are poorly resolved. The cAMP/PKA pathway is 
involved in the adrenergic stimulation of TH activation in BAT by cold stimulus and in 
the pineal gland by photoperiodic response [150, 151]. In birds, TSH – derived from pars 
tuberalis – is also suggested to act via cAMP to induce D2 in mediobasal hypothalamus 
[153]. Our results suggest PACAP as a novel cAMP-dependent mediator of D2 activity. 
 
7.1.2. Tanycytes express the PAC1R PACAP receptor 
 Having established in vitro that PACAP is able to activate DIO2 transcription we 
aimed to identify D2 expressing cell types and brain regions where PACAP-mediated 
regulation of TH activation could be relevant in vivo. We demonstrated by 
immunohistochemistry that tanycytes express the PAC1R receptor. Tanycytes have 
exclusive D2-expression in hypothalamus therefore these cells have critical role in the 
regulation of HPT axis providing the main T3-source. Alterations in tanycytic D2 activity 
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is known to exert major impact on the feedback of the HPT axis demonstrated in bacterial 
infection model of non-thyroidal illness syndrome [81]. In contrast to tanycytes PAC1R 
expression could not be detected in cortical and hippocampal D2-expressing astrocytes 
however it should be noted that PAC1R expression was demonstrated in reactive 
astrocytes and these cells could express VPAC1 or VPAC2 receptors showing similar 
affinity for PACAP and VIP. Thus under certain conditions PACAP could act on TH 
activation within these regions [212, 213]. 
 
7.1.3. PACAP affects the feedback and development of HPT axis 
 To test, whether PACAP mediated modulation of D2 expression and HPT function 
is functional in vivo, we performed acute intracerebroventricular PACAP administration. 
PACAP resulted in remarkable alterations in the HPT axis of CD1 mice. The increased 
mediobasal hypothalamic D2 activity confirms the presence of functional receptors – 
identified by immunohistochemistry – on tanycytes because D2 expression is confined to 
these cells within this region. The elevated T3 generation resulted in suppressed TRH in 
the paraventricular nucleus despite the putative stimulatory effect of PACAP on the TRH 
neurons which was overwritten by the increased negative feedback. The decreased Trh 
was manifested in decreased Tshb transcription demonstrating that PACAP suppressed 
the HPT axis via tanycytic D2. The serum TSH bioactivity and free T4 level were 
unaffected however taking into account the series of required transcriptional events and 
the stability of circulating T4 this parameter was unlike to be affected within 4-hours after 
treatment. Our data established PACAP as a novel modulator of hypothalamic TH 
economy. The hypothalamus is densely innervated by PACAP-containing fibers and 
several nuclei of hypothalamus express PACAP. [214-217]. Interestingly, a subdivision 
of TRH neurons was found to express PACAP and exerted a reverse, orexigenic effect on 
energy homeostasis [88]. Additionally, taking into account the localization of tanycytes 
in the wall of third ventricle the PACAP-mediated modulation of hypothalamic TH 
activation could be affected by external sources via the cerebrospinal fluid. In contrast 
with hypothalamus in the cortex and hippocampus significant difference was not 
observed however – especially in case of hippocampus – D2 activity showed a tendency 
for increase. Taken together with the immunohistochemical results these data raise the 
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possibility that D2 could be targeted in this region by PACAP via VPAC1 and VPAC2 
receptors or indirectly. 
 The TH status and TH activation of heterozygous PACAP-deficient (PACAP+/-) 
mice were tested to reveal long-term effects of PACAP on TH economy and HPT axis. 
The decreased serum free T3 and T4 levels together with suppressed TSH bioactivity 
suggested central hypothyroidism. As a consequence, the cortical and hippocampal D2 
activities were elevated compensating the decreased TH availability while in regions with 
crucial impact on HPT axis – in the mediobasal hypothalamus and in the pituitary – D2 
activity was not affected. Similar signs of central hypothyroidism are known to exist in 
the infection model of non-thyroidal illness [81]. Taken together with the potent 
antiinflammatory effect of PACAP raised the possibility that an altered immune state 
could result the observed phenotype [218]. However measuring serum inflammatory and 
antiinflammatory cytokine concentrations did not indicate difference in the 
immunological state of genotypes. 
 Therefore we hypothesized that the maturation – rather than the adult state – of the 
HPT axis could be affected in PACAP-deficient mice. HPT axis is highly sensitive for 
the alterations in TH availability within the postnatal period when the set point of the axis 
is established as demonstrated in Dio3 knock-out mice where the local hyperthyroidism 
results in decreased activity of the HPT axis and consequent long-term suppression of 
HPT axis manifested in hypothyroidism persisting also in adult mice [143]. Measuring 
the expression of genes involved in TH metabolism, transport and reception revealed 
increased Dio3 expression in PACAP-deficient mice. The elevated TH inactivation 
during this critical period of HPT axis could lead to altered set point formation to lower 
TH availability and results the lack of compensation of hypothyroid periphery. Further 
studies are required to clarify how Dio3 transcription is modulated by PACAP in 
hypothalamus, especially within this critical window of the maturation of HPT axis. 
  
 The revealed complex involvement of PACAP in the regulation and development 
of HPT axis and the proposed underlying mechanisms are depicted in Fig. 32. 
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Figure 32. Schematic depiction of PACAP-mediated regulation of the HPT axis 
PACAP interacts with hypothalamic thyroid hormone signaling at multiple levels. Dotted lines represent 
suggested processes still need to be conformed directly. PACAP upregulates D2 in tanycytes viaPAC1R 
as the expression of this PACAP-specific receptor is demonstrated but the additional involvement of 
VPAC1/2 cannot be presently ruled out. D2-generated T3 downregulates TRH expression in the PVN and 
counteracts the suggested direct stimulatory effect of PACAP on TRH neurons. T3 can downregulate TRH 
expression directly and by interfering with cAMP induced TRH upregulation and this second mechanism 
can also impact PACAP expression. PACAP also plays a hypothetic role in HPT set point formation 
during development. 
 
 
7.1.4. Thyroid hormones modulate Adcyap1 (PACAP) gene transcription 
 In order to test whether the interaction between TH and PACAP signalization is 
bidirectional the responsiveness of Adcyap1 gene – encoding PACAP – to THs was 
studied. The 3 kb 5’ flanking region of mouse Adcyap1 gene was found to be insensitive 
for different T3 concentrations indicating PACAP synthesis – at least on transcriptional 
level – is not targeted by THs. However, we found that the cAMP/PKA pathway-mediated 
induction of Adcyap1 promoter is interfered by liganded TR suggesting that THs are able 
to modulate the Adcyap1 gene transcription indirectly. The proposed mechanism could 
be the interfered CREB phosphorylation by ligand-bound TR based on the protein-protein 
interaction between TR and CREB [219, 220]. Hypo- and hyperthyroid mice were 
generated to test the in vivo significance of the altered TH levels on Adcyap1 gene 
transcription. In general, Adcyap1 transcript was found to be unaffected in various brain 
regions but it was decreased by hyperthyroidism in the parabrachial nucleus. Importantly, 
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this region is in bidirectional connection with hypothalamic areas involved in the central 
regulation of feeding and energy homeostasis. The parabrachial nucleus receives 
inhibitory input from orexigenic AgRP neurons of arcuate nucleus [221] and sends inputs 
into PVN, ventromedial nucleus [214] and lateral hypothalamus [222]. Adcyap1 level was 
also altered in the pituitary, a major target of PACAP action affecting the hypothalamo-
pituitary-gonadal axis by modulating LH and FSH secretion [223, 224] and hypothalamo-
pituitary-adrenal axis [225] via affecting ACTH production. Further studies are required 
to elucidate the significance of these findings. 
 
7.2. CHARACTERIZATION OF MARCH6 AS D2 UBIQUITIN LIGASE 
7.2.1. Expression profile of March6 
 It has been demonstrated, that tanycytes coexpress the MARCH6 ubiquitin ligase 
with D2 [164]. We also aimed to identify extrahypothalamic brain regions and tissues 
where March6 is expressed therefore its expression profile was studied in adult Wistar 
rats with semi-quantitative RT-PCR. March6 expression was compared with Wsb1 
focusing predominantly tissues where the D2 is the preferred activating deiodinase. 
March6 showed strong expression in kidney, skeletal muscle, cortex, heart and 
hypophysis where the subunit of the other D2-specific ubiquitin ligase, Wsb1 is also 
expressed. A striking difference in ligase expression was observed in brown adipose 
tissue (BAT) where March6 was poorly expressed while strong Wsb1 expression was 
found. BAT is one of the best characterized targets of TH action. The induction and 
maintenance of UCP1-mediated thermogenesis requires a tight regulation of D2 activity 
[226]. Recently it is not fully understood how this process is affected by the ubiquitination 
of D2. Reduced ubiquitination and the increased deubiquitination of D2 could increase 
local T3 generation however further studies are required to clarify the involvement of this 
machinery in thermogenesis. Interestingly, we did not detect D2 specific ubiquitin ligase 
expression in the thyroid gland, suggesting that D2 regulation could be independent from 
UPS in this tissue. However it is important to note that other, recently unknown, ubiquitin 
ligases for D2 could exist while on the other hand D2 is not the exclusive substrate of 
WSB1 and MARCH6. WSB1 was reported as ubiquitin ligase of HIPK2 kinase involved 
in hypoxia response [227]. MARCH6 was found to target squalene monooxygenase (SM) 
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for proteasomal degradation [208] and MARCH6 is also important member of quality 
control system of ER. 
 
7.2.2. Characterization of the human MARCH6 promoter 
 While the involvement of MARCH6 in ERAD machinery is well documented 
however the regulation of MARCH6 gene is poorly characterized. Therefore the 5’ FR of 
human MARCH6 was cloned and analyzed by in silico transcription factor binding site 
prediction using the TRANSFAC database and the TESS algorithm. Focusing primarily 
on regulators involved in the transcriptional control of human DIO2 gene we identified 
several potential CREB and NF-κB binding sites in the 5’ FR of human MARCH6 gene. 
Canonical TRE could not be detected however TRE-half sites were predicted and in the 
close proximity of TSS and SP1 binding site rich region was identified. The effectivity of 
these putative sites was tested on the 3.5 kb fragment of human MARCH6 gene.  
 The results of luciferase promoter assay suggest an opposite regulation between 
MARCH6 and DIO2 gene while MARCH6 promoter activity is suppressed by NF-κB and 
cAMP-CREB intracellular signals that are strong activators of DIO2 transcription [119, 
155]. Therefore MARCH6-assisted ubiquitination provides an indirect mechanism acting 
on the post-translational level to affect D2 activity in presence of active NF-κB and 
cAMP/PKA signaling pathways. The in vivo relevance of these signals in TH activation 
is well documented. The NF-κB pathway is affected by numerous receptors involved in 
immune system-related signalizations [228] and it was previously shown that acute 
inflammation evoked by LPS administration induces D2 expression in tanycytes [81]. It 
is not completely understood whether LPS is directly sensed by tanycytes via Toll-like 
receptor 4 (TLR) or inflammatory signals produced by the immune system (e.g. 
interleukins, tumor necrosis factor etc.) are involved in NF-κB-mediated alterations in 
gene expression. However, it was clearly demonstrated that the induction of D2 in 
tanycytes by acute inflammation has a major impact on thyroid axis offering a 
mechanistic model for the molecular pathogenesis of non-thyroidal illness [8, 81]. 
According to this concept the increased T3 generation via elevated D2 levels in tanycytes 
results in local hypothalamic hyperthyroidism and as a consequence leads to the 
suppression of the HPT axis. Since March6 expression was found in tanycytes [164] and 
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our recent data demonstrated the negative regulation of March6 expression by the NF-κB 
pathway, it can be suggested, that the local increase of D2 activity – beside de novo 
protein synthesis – could be further supported by the decreased inactivation capacity via 
the ubiquitin-proteasome system.  
 The cAMP/CREB intracellular signalization has central role in transducing the 
noradrenergic-stimulation to TH activation in brown adipose tissue and pineal gland and 
MARCH6 could provide an additional, posttranslational mechanism to support increased 
T3 generation. 
 The MARCH6 gene promoter belongs to the GC-rich promoters and SP1 is usually 
an important factor involved in the regulation of this type of promoters. Additionally, the 
transcription factor binding site analysis of MARCH6 5’ FR region revealed several 
putative SP1 sites. To test the importance of SP1 in the regulation of MARCH6 expression 
the region contains these sites was deleted and promoter activity was measured revealing 
significant decrease in basal promoter activity that confirmed the involvement of SP1 in 
the regulation of MARCH6 transcription.  
 We revealed an important difference in the SHH responsiveness of MARCH6 and 
the subunit of other D2 ubiquitin ligase, the WSB1 demonstrating a functional difference 
between the two ligases of D2. WSB1 has the ability to transduce the antagonistic effect 
of proliferative SHH on T3 a known inducer of differentiation [161] while our data 
indicate that MARCH6 is not regulated by the effector transcription factor of SHH 
signalization, Gli2. These data suggest a distinct role in the posttranslational control of 
D2 enzyme while MARCH6 could refer for short half-life and instability; additionally 
WSB1 interlinks two major morphogenetic signaling pathways, governed by Sonic 
hedgehog and THs. This putative role of WSB1 could be important during development 
and also in adulthood, especially in cell types like tanycytes where all members required 
for the SHH-mediated regulation of TH activation are expressed. Tanycytes due their 
abundant D2 expression are the major source of hypothalamic T3 therefore the signals 
affecting tanycytic D2 activity have a systemic role via the HPT axis as it was shown in 
the pathogenesis of LPS-induced acute inflammation [81]. Additionally, tanycytes are 
recently identified as the potential source of newborn neurons in the adult hypothalamus 
[229, 230]. In this process a precise balance is required between the proliferative signals 
like SHH and differentiative agents as THs. Therefore the SHH-driven downregulation 
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of T3 generation could serve as important switch point in adult hypothalamic 
neurogenesis. 
 The Wnt pathway along with SHH acts as major regulator in the determination of 
dorsoventral axis and potent regulator of proliferation-differentiation balance. Similarly 
to SHH the Wnt can also support proliferation of progenitors promoting cell division and 
interfering with the exit from cell cycle [231]. This process was shown to be essential in 
the adult hippocampal neurogenesis [232]. The importance of Wnt pathway in the 
regulation of TH metabolism was shown in previous studies and revealed an antagonistic 
effect of Wnt on the T3 level which acts both on the TH activating and inactivating 
enzymes on transcriptional level [202]. However it was not clarified whether Wnt affects 
the post-translational control of T3 generation. We demonstrated that the MARCH6 
promoter was suppressed by β-catenin, the effector of Wnt signaling. Importantly, the 
molecular elements of Wnt signalization are expressed in tanycytes therefore the Wnt 
could be involved in the fine-tuning of proliferation-differentiation equilibrium via 
MARCH6 mediated ubiquitination of D2 and consequently the T3 generation. 
 The regulation of MARCH6 expression and involvement in the posttranslational 
control of D2 is summarized in Fig. 33. 
 
7.2.3. Contribution of ubiquitination to the regulation of D2 in brown adipose 
tissue (BAT) 
 Local induction of TH activation is critical in the cold response of BAT [226]. It 
was demonstrated that the activation of cAMP/PKA pathway by adrenergic stimuli 
induces de novo D2 synthesis however it remained to be elucidated how the 
posttranslational regulation of D2 enzyme is affected during BAT thermogenesis. To 
target this question the expression of genes involved in the ubiquitin-mediated regulation 
of D2 were monitored during and after the cold induction of BAT. Our in vitro data 
indicated that March6 could be targeted by the cAMP/PKA pathway activated in BAT by 
cold stimulus. However March6 mRNA level during cold stress was found to be stable. 
In contrast to March6 the Wsb1 ligase subunit expression showed a remarkable 
temperature-sensitivity. Transferring mice to 4 °C Wsb1 expression is rapidly increased 
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by 2-fold and remained constantly upregulated during cold induction. After returning to 
room temperature Wsb1 mRNA felt to the level of non-induced control after the first hour. 
 Taken together these data suggest that cold-induced alterations in the ubiquitination 
of D2 do not contribute directly to the increased T3 production in BAT. March6 was 
shown to be insensitive for cold induction of BAT. In contrast, Wsb1 showed an opposite 
pattern than it was expected however the precise function of this phenomenon should be 
addressed by further investigations. Presently precise structural data are not available that 
would explain the intramolecular conformational changes and intermediates during 
catalytic cycle in D2. However a selenenyl-sulfide intermediate state is suggested in D3 
by studies based on the structural analysis of D3 protein. Comparison of homologies 
between D2 and D3 revealed that D2 lacks a critical cysteine proposed to be important in 
the reduction of deiodinases therefore D2 could be trapped in this inactive state and could 
be facilitated for ubiquitination [142]. This hypothesis should be clarified by further 
investigation however the presence of one of this inactive intermediate D2 could affect 
the active conformation of the interacting partner in D2 homodimers. Therefore its 
clearance could be beneficial in the achievement and maintenance of elevated D2 activity. 
 
7.2.4. Topology of D2-MARCH6 interaction 
 The involvement of MARCH6 protein in the posttranslational regulation of D2 has 
been previously demonstrated but its precise action is remained to be clarified. Using 
FRET method we documented direct protein-protein interaction between MARCH6 and 
D2 in living mammalian cells. We have also shown that this interaction is realized 
between the N-terminus of MARCH6 protein and the C-terminal globular domain of D2. 
Taking into account the ambiguous membrane topology of MARCH6 [233, 234] our 
interaction study also addressed the potential localization of the MARCH6 C-terminus 
but we observed that this part of the protein is not involved in the recognition of D2 
directly. It is important to note that the N-terminus of MARCH6 carries RING-domain a 
common structural unit of the vast majority of E3 ubiquitin ligases or ligase complexes. 
Therefore the N-terminus of MARCH6 protein incorporates both of the most important 
function of an E3 ligase – at least in case of D2 – the facility of substrate recognition and 
the ubiquitin-conjugation catalytic activity. 
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7.2.5. Thyroid hormone-dependence of MARCH6-mediated regulation of D2 
 Promoter analysis did not revealed canonical positive TRE consensus sequence in 
the 3.5 kb 5’ FR of human MARCH6 gene but several TRE half-sites were predicted. 
Taking into account the numerous genes known to be regulated by THs in the absence of 
a classical TRE (e.g. DR4) sequence, we tested the effect of T3 on MARCH6 promoter 
activity with dual luciferase promoter assay. However, 3.5 kb FR of human MARCH6 did 
not respond to T3 indicating the D2 ubiquitination via MARCH6 is not regulated by THs 
on transcriptional level. 
 The product- or intermediate compound-driven feedback is an important and 
common mechanism of the regulation of enzyme activity allowing the rapid control of 
biological processes. Usually this regulation is carried out by the allosteric action of a 
product (or another downstream metabolite) of the enzyme. However, as an untypical 
example of enzyme regulation D2 is regulated by its substrate, T4. In this case, T4 serves 
as a feedforward regulator inhibiting the activity of the enzyme by increasing the 
accessibility of D2 by its ubiquitin-conjugating apparatus. The accurate mechanism is still 
remained to be elucidated whether this phenomenon is originated from the catalytic cycle 
of D2 or is related to a region located outside of the active center. The increased 
ubiquitination of D2 by T4 results an inactive enzyme conformation or leads to its 
degradation in the 26S proteasome. Previous studies showed the importance of WSB1 
ligase subunit within this process. Using FRET studies we found that the D2- MARCH6 
interaction is also positively controlled by T4 that clearly indicates the involvement of 
MARCH6 in the substrate-mediated ubiquitination of D2. Therefore both known E3 
ligases of D2 are involved in substrate-mediated downregulation of TH activating 
capacity. 
 The regulation of MARCH6 expression and involvement in the posttranslational 
control of D2 is summarized in Fig. 33. 
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Figure 33. Schematic depiction of the regulation and involvement of MARCH6 in D2 ubiquitination  
 
7.2.6. Construction of a 3-FRET approach to study parallel the interactions of 
D2 with the two E3-ligases 
 The previously revealed T4-mediated action of MARCH6 raised the question 
whether ligase preference exists in the substrate-mediated ubiquitination of D2. 
Importantly, tanycytes are the only cell type in the brain where D2 could be regulated by 
both of its E3 ligases therefore the coordinated action of WSB1 and MARCH6 regulating 
the T3 generation could have a role in the regulation of HPT axis. Standard FRET design 
is restricted to the investigation of interaction between two proteins therefore it cannot be 
used to study the interaction between D2 and its two E3 ligases at the same time. To 
overcome this limitation we aimed to set-up a 3-FRET approach by taking advantage of 
the properties of EYFP. The EYFP is able to serve both as an acceptor and a donor in 
appropriate FRET pairs. In this application the D2 was fused to EYFP therefore it can be 
a FRET acceptor for ECFP-fused MARCH6 while acts as a donor for mCherry-fused 
WSB1. This system was capable to monitor the interactions between the D2 and its 
ubiquitin ligases within the same living cell. Using this approach we demonstrated that 
both E3 ligases has associated with D2-dimers in the lack of T4 and both of them are 
involved at a similar level in T4-dependent D2 inactivation and the process did not 
demonstrate ligase preference. These data suggest that the substrate-mediated inhibition 
is based on a conformational change within the D2 allowing the availability of the 
recognition surface for the ubiquitin ligases. It is important to note that this recognition 
surface of D2 is not yet identified due lacking structural data. However, these results 
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indicate that significant interference does not exist between the two E3 ligases that 
suggest the existence of different recognition motifs. It was previously shown that the 
subunits of ECFWSB1 ligase complex are closely associated to D2 dimers in the ER [162]. 
These results also indicate that MARCH6 has high affinity to D2 although it is not 
incorporated of the ECFWSB1 ligase complex. 
 
7.3. STRUCTURAL BACKGROUND OF THE UBIQUITINATION OF DEIODINASES 
7.3.1. Molecular background of stability and ubiquitination of deiodinases 
 Ubiquitination mediated processing of D2 is presently the most sensitive and 
quickest way to regulate TH activation. In order to better understand the mechanism of 
regulation of TH metabolism by ubiquitination, we aimed to identify the minimal 
requirements of ubiquitination of deiodinases. Previous studies were based on deletion 
and mutation of D2-specific motifs and targeted the identification of elements and motifs 
involved in the ubiquitination of the D2 protein [161, 162, 203]. We applied a reverse 
strategy incorporating D2-specific elements into D1 a non-ubiquitinated and stable 
deiodinase backbone resulting a D1-D2 chimeric protein. The previously used approach 
was capable to predict structural elements – or the parts of these elements – with important 
role in ubiquitination by detecting the interfered ubiquitination in absence of these 
regions. However, this strategy is unable to dissect precisely whether a specific element 
is an independent degradation unit or only part of such an element without the capacity 
to induce ubiquitin-mediated instability alone. For example this approach could not be 
used to resolve whether the identified element composes a discrete motif or represents a 
portion of a larger interaction surface, or alternatively, its function is the scaffolding of 
recognition epitope for ubiquitin ligases. The last case could result altered ubiquitination 
by misfolded epitope in deletion studies. Therefore we applied a reversed strategy to try 
to convert a non-ubiquitinated deiodinase into ubiquitination-susceptible form by the 
incorporation of the complete and functional element. Using this approach combinations 
of D2-specific elements were tested to reveal the sufficient and required set of molecular 
elements needed to turn the stable D1 protein to a destabilized D2-like protein that is 
sensitive to ubiquitination. 
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 We found that the incorporation of one or two ubiquitin-carrier lysines of D2 did 
not result in significant alteration in the half-life of the chimera and no ubiquitinated 
forms could be revealed. In contrast, simultaneous mutations of these lysines within the 
D2 stabilized the protein and led to loss of T4-mediated downregulation via ubiquitination 
[162]. Together these data directly prove that other D2-specific elements that are not 
present in D1 are required to the recognition of the protein by the ubiquitin-conjugating 
apparatus, since the insertion of ubiquitin-carrier lysines without additional motifs was 
unable to target the chimeric protein for the UPS. We then studied the impact of the 
insertion of the D2-specific instability-loop into the chimera carrying lysine mutation(s) 
in the homologue position compared to D2 protein. Alignment of D1 and D2 proteins 
revealed an 18 amino acid-length sequence which is unique in D2 proteins and its 
existence but not its sequence is conserved among species. A previous study focused on 
the characterization of the effect of this region on the ubiquitin-mediated regulation of 
D2 showed that the critical region of this loop is the N-terminal 6 amino acids. The 
deletion of this region – similarly to the deletion of the whole loop – stabilized the D2 
protein while the deletion of the C-terminal 12 amino acids has little effect on the protein 
half-life [203]. Therefore in this study we applied the incorporation of this 6 amino acid-
length loop into chimeric deiodinases. Chimeras containing ubiquitin-carrier lysines and 
the loop sequence showed decreased half-life without detectable signs of the involvement 
of the ubiquitin-proteasomal system since no high molecular mass forms could be 
identified and inhibition of proteasome did not increase the activity of the enzyme. It is 
unlikely that this short region could interact directly with ubiquitin ligases of D2. 
However this flexible loop may have an important role in T4-induced conformational 
changes underlying the acceptability of D2 by the E3 ligases. These findings raise the 
possibility that the inherent instability of D2 is not exclusively derived from the UPS but 
other non-proteasomal mechanisms could be involved as shown for iron regulatory 
protein 2 and IKBA [235, 236]. The combined insertion of lysine residues and the loop-
sequence was accompanied by the addition of a SEC62 domain to allow sorting of the 
protein to the ER, the cellular compartment where D2 – uniquely among deiodinases – is 
located in the cells. Interestingly, these properties resulted high molecular mass 
ubiquitinated forms and decreased stability of the chimera indicating that the applied 
elements were sufficient and required to induce the ubiquitination of the chimera. It was 
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previously shown that the SEC62-fusion used for the direction of the chimera to the ER 
abolished deiodinase activity [203]. As a consequence the effect of proteasome inhibitors 
on the activity of the ER directed D1-D2 chimera could not be tested by activity assay. 
Therefore to prove the specificity of this ubiquitination carried out by D2 ubiquitin ligases 
we tested the interaction between chimeras and WSB1 ligase subunit and MARCH6 
ligase as discussed in the following section. The effect of the investigated structural 
elements on the stability and ubiquitination of deiodinases are summarized in Fig.34. 
 
 
Figure 34. Summary of the effects of structural elements on D2 stability and ubiquitination 
 
7.3.2. Importance of D2-specific elements in the recognition by ubiquitin ligases 
 We also studied the recognition criteria of D2-specific E3 ligases to exclude that 
ubiquitination of the generated chimera was a result of unspecific mechanisms triggered 
by either the cytotoxic levels of overexpressed proteins or non-specific interaction due to 
their high concentration or by misfolding. We also aimed to identify the required elements 
for D2 ligases to recognize a deiodinase protein as a substrate. These measurements 
revealed that the lysine residues in combination with instability-loop or the ER-
localization alone are insufficient to allow an interaction between deiodinases and WSB1 
or MARCH6 E3 ligases. These data are in accordance with our above demonstrated 
findings on testing the stability of chimeric deiodinases that the chimeras contained 
separately or in combination the lysine residues and instability-loop were not 
ubiquitinated. However the insertion of these elements into ER-directed D1 backbone 
(SEC62-D1-2K-loop) resulted in detectable interaction with the WSB1 ligase subunit 
while MARCH6 was still unable to recognize this chimera. These data together indicates 
that a specific D2 ligase can catalyze the ubiquitination of the lysine- and loop-containing, 
ER-targeted chimera. Additionally, the difference in binding of this chimera by the two 
known D2 E3 ligases suggests the different structural background and mechanism of 
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action of WSB1 and MARCH6 on D2. The anticipated difference in ubiquitin-
conjugation raises the possibility of different function of D2-specific E3 ligases in the 
regulation of TH activation. 
 The ubiquitin-code – defining the downstream processing of proteins tagged by 
ubiquitin or multiple ubiquitin moieties – is under intensive examination. However, it has 
been poorly understood how the quality of the polyubiquitin chain determines the further 
processing of protein. A subset of these ubiquitin signals has well characterized functions 
– e.g. K48-linked and K63-linked polyubiquitin chains as canonical degradative and non-
degradative signals, respectively. In combination with UBC6 E2 ubiquitin conjugating 
enzyme (yeast orthologue of UBE2J) the Doa10 ubiquitin ligase (yeast orthologue of 
MARCH6) was shown to be involved in the synthesis of the relatively rare K11-linked 
polyubiquitin chain formation that function is poorly understood [182]. The involvement 
of UBE2J and MARCH6 in the ubiquitination of D2 was shown in previous studies [160, 
211] raising the possibility that this non-canonical, K11-linked polyubiquitin chain could 
play a role in the regulation of TH activation. Therefore further studies are required to 
target the characterization of the precise architecture of the ubiquitin signal built on D2 
focusing on the occurrence of chain-types and their function in the regulation of the D2 
enzyme. It is also remains to be clarified whether the equilibrium between reversible 
ubiquitination and degradation of D2 is determined by the capacity and efficiency of 
ubiquitination, deubiquitination and membrane extraction or these pathways are 
controlled by different ubiquitin motifs. 
 The effect of the investigated structural elements on recognition by D2 ubiquitin 
ligases are summarized in Fig.34. 
 
7.3.3. Effect of threonine/alanine polymorphism in D2 on the interaction with its 
ubiquitin ligases 
 Previous studies based on statistical correlations suggested linkage between genetic 
variant of human D2 and obesity, insulin secretion, risk of type 2 diabetes [237-239] and 
altered response for TH replacement therapy [240]. However, the importance of T92A 
substitution in D2 protein and how this single amino acid change affects the enzyme 
properties are poorly understood. Previous results indicated decreased Vmax and 
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unaffected KM and stability [126]. Importantly, the 92th amino acid is the first residue of 
the instability-loop of D2. Therefore 3-FRET measurements were applied to understand 
whether the ubiquitin-mediated processing of polymorphic Ala92 D2 is altered compared 
to the wild-type Thr92 D2. We demonstrated that the interactions with WSB1 and 
MARCH6 were unaffected by the polymorphism. Interestingly, the T4-mediated increase 
in association with MARCH6 was interfered by T92A mutation while the induction of 
WSB1-D2 interaction was similar between wild-type and polymorphic D2. Since 
polymorphic D2 is suggested to have longer half-life compared to wild-type, our findings 
revealed a mechanism that could contribute to this phenomenon [128]. These results also 
support our previous findings that WSB1 and MARCH6 could recognize different 
interaction surface on D2 (Fig. 34). 
 
7.3.4. Relationship between deubiquitination and extraction of D2 from the ER 
 Cytosolic soluble ubiquitinated proteins can be directly processed by the 
proteasome. However, ER-resident proteins need to be extracted from the ER before their 
degradation can occur. This step includes ATP-dependent processes carried out by 
multiprotein-complex organized by the p97 hexamer [241] and Atx3 deubiquitinase 
[242]. In ERAD, this is a critically important step in the degradation of misfolded proteins 
however for specific targets, e.g. D2 this process has an additional feature. The 
ubiquitination of D2 enzyme leads to abolished enzyme activity however this process 
does not result in obligatory protein degradation, active D2 conformation could be 
recovered by deubiquitination allowing reversible ubiquitin-mediated regulation. 
Therefore this mechanism provides a rapid and economic way to control the T3 generating 
capacity. D2 deubiquitination was suggested to play a role in the generation of different 
responsiveness of D2 activity to T4 in specific brain regions. For example in the cortex, 
D2 activity in astrocytes responds to T4 in a homeostatic manner while tanycytes in the 
hypothalamus do not and in accordance, not astrocytes, only tanycytes express the D2 
deubiquitinase USP33 that could allow a rescue from T4 induced downregulation of D2 
activity [243]. However, regaining D2 activity by deubiquitination can occur only before 
membrane-extraction. Therefore the membrane extraction of ubiquitinated D2 could be a 
rate limiting step regulating the equilibrium between reversible inactivation of D2 and its 
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irreversible degradation. Consequently, this system is a key factor determining the 
amount of ubiquitinated D2 available for its deubiquitinases USP33 and USP20 [163]. 
However the inhibition of p97/Atx3 complex did not lead to increased D2 activity. 
Therefore we dissected with FRET the protein-protein interactions underlying this 
phenomenon. We observed a decreased interaction between the globular domains of the 
D2 homodimer in presence of p97 inhibitor, EERI and the interaction gained insensitivity 
to T4 in the presence of EERI. Since ubiquitination is known to destabilize D2 
homodimers we concluded that the equilibrium in the ubiquitination state of D2 shifted 
to the inactive, ubiquitin-conjugated state providing mechanistic explanation for the 
observed unchanged D2 activity in preliminary studies. However it remains to be 
answered how the abolished ER membrane extraction affects the ubiquitination or 
deubiquitination. Therefore we also measured the interaction between the USP33 
deubiquitinase and D2 revealing decreased recognition of the D2 by its deubiquitinase 
enzyme upon the inhibition of p97/Atx3 complex. These data suggest that the enrichment 
of ubiquitinated D2 in the ER due to the loss of extraction capacity is compensated by 
decreased deubiquitination. Importantly, the action of USP33 is not restricted to D2 
therefore the alteration of ubiquitination state of its other substrates could affect the 
amount of available deubiquitinase enzyme for D2. Our data indicate strong link between 
USP33-mediated deubiquitination and p97 membrane extraction complex. This finding 
is in accordance with previous observations revealing the USP33 itself as a target of 
ubiquitination and interestingly this process is depends on the presence and activity of 
p97 [244].  
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8. CONCLUSIONS 
 The performed studies aimed to better understand the impact of thyroid hormone 
activation on the HPT axis along with molecular mechanisms underlying the regulation 
of type 2 deiodinase, the key player of thyroid hormone activation. 
 Our data demonstrated that cAMP-mediated activation of Dio2 gene by PACAP in 
tanycytes has a striking effect on the HPT axis by suppressing TRH neurons of the 
hypothalamic paraventricular nucleus via elevated local T3 production, despite the earlier 
proposed stimulatory effect of PACAP on TRH. We also found that PACAP affects the 
maturation of the HPT axis. A bidirectional interaction was found between thyroid 
hormones and PACAP since the liganded thyroid hormone receptor interferes with the 
cAMP-mediated induction of the PACAP encoding Adcyap1 promoter although the 
consequences of this mechanism was region-specific in vivo. 
 D2 ubiquitination represent the most efficient way to regulate D2 activity. To better 
understand the mechanism of D2 ubiquitination, we characterized the MARCH6 
ubiquitin ligase in comparison with the WSB1 ligase subunit. Both of these D2 ubiquitin 
ligases are widely expressed with alterations in expression level. Major differences were 
found in the regulation of the two ubiquitin ligases. In contrast to WSB1, MARCH6 was 
found unresponsive to important regulators of thyroid hormone metabolism like Sonic 
hedgehog, and cold stress. These findings suggested that MARCH6 could be responsible 
for basal instability of D2 while WSB1 represent the inducible component of the D2 
ubiquitination machinery. 
 We clarified the topology of the D2-MARCH6 interaction by demonstrating direct 
protein-protein interaction between the D2 globular domain and the N-terminal RING-
domain of MARCH6 in living cells. We proved that the interaction is increased upon T4 
exposure as an underlying mechanism of substrate induced downregulation of the D2 
protein. In contrast, the expression of MARCH6 was not affected by thyroid hormones.  
 Using chimeric recombinant deiodinases we identified the minimal combination of 
structural elements required and sufficient for the instability and targeting of deiodinase 
proteins for ubiquitination. Additionally, our data revealed differences in the structural 
background of the recognition of D2 by its ubiquitin ligases. Differences were also 
observed between wild-type and T92A polymorphic D2 protein with respect to MARCH6 
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ligase binding since the polymorphism abolished the T4-sensitivity of D2-MARCH6 
interaction, while did not alter WSB1 binding under this conditions.  
 Our data indicated a strong functional link between D2 deubiquitination and its 
extraction from the ER membrane indicating this step could be rate-limiting during 
reversible ubiquitination. 
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9. SUMMARY 
 The major secretory product of the thyroid gland is the thyroxine (T4), a stable 
prohormone with low affinity to thyroid hormone nuclear receptors. T4 needs to undergo 
local activation to T3 via type 2 deiodinase (D2) to evoke thyroid hormone action. This 
process is crucial in the brain where T4 has poor access to the brain parenchyma via the 
blood-brain and CSF-brain barriers. Therefore D2 is under tight control including 
transcriptional elements and the posttranslational ubiquitin-proteasome system. We 
aimed to better understand the molecular regulation of D2 and its impact on the HPT axis. 
 We described that PACAP affects the activity of the HPT axis via cAMP-mediated 
activation of D2 encoding Dio2 in tanycytes of the mediobasal hypothalamus. The 
increased T3 generation suppresses TRH expression in the hypothalamic paraventricular 
nucleus despite the earlier proposed stimulatory effect of PACAP on TRH expression. 
PACAP was also found to play a role in the maturation of HPT axis by affecting the local 
thyroid hormone metabolism during the establishment of the set point of HPT axis. 
 D2 is targeted by two ubiquitin ligases, the WSB1 complex and MARCH6. We 
demonstrated that similarly to Wsb1 the March6 gene is widely expressed in different 
brain regions and tissues while both were absent in thyroid gland. We demonstrated the 
role of MARCH6 in the regulation of D2 based on protein-protein interaction in living 
cells. This interaction occurs between the globular domain of D2 and N-terminus of 
MARCH6 and sensitive for T4 – similarly to D2-WSB1 interaction – indicating the 
contribution of both ligases in the substrate-mediated inactivation of D2. 
 Constructing chimeric deiodinases we identified the minimal structural elements 
required for the instability and ubiquitination of a deiodinase protein and demonstrated 
differences between the recognition of D2 by the two ubiquitin ligases. Using a protein-
protein interaction approach we observed intense connection between ER-extraction of 
D2 and its deubiquitination suggesting that this process represents a rate limiting step in 
the reversible ubiquitination of D2. 
 As conclusion our data contribute to the better understanding of the complex 
regulation of D2 enzyme the crucial element of thyroid hormone action in the brain.  
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10. ÖSSZEFOGLALÁS 
 A pajzsmirigy fő szekretoros terméke a stabil prohormon tiroxin (T4), alacsony 
affinitással a pajzsmirigyhormon magi receptorok felé. A T4-nek lokálisan T3-má kell 
alakulnia a kettes-típusú dejodáz (D2) enzim által a szöveti pajzsmirigyhormon hatás 
kifejtéséhez. E folyamat az agyban kiemelt jelentőségű, mivel a T3 rendkívül alacsony 
mértékben jut át a vér-agy és az CSF-agy gáton. Ezért a D2 komplex transzkripcionális 
és poszttranszlációs szabályozás alatt áll. Célunk a D2 molekuláris szabályozásának jobb 
megértése és annak jelentőségének feltárása a HHP tengely működésében. 
 Leírtuk a HHP tengely PACAP-általi szabályozását a D2-t kódoló Dio2 gén cAMP-
általi aktiválásán keresztül tanicitákban, a mediobasalis hypothalamusban. Az így 
megemelkedett T3 előállítás gátolja a TRH expressziót a hypothalamus paraventricularis 
magjában a PACAP korábban feltételezett TRH-t stimuláló hatása ellenére. A PACAP 
fontos szerepet játszhat a HHP tengely fejlődésében a helyi pajzsmirigyhormon 
metabolizmus szabályozásával a tengely egyensúlyi pontjának kialakulása során. 
 A D2-t szabályozásában két ubikvitin ligáz vesz részt: a WSB1 komplex és a 
MARCH6. Azonban a MARCH6 tulajdonságai és szabályozása kevéssé feltárt. 
Eredményeink a March6 széleskörű szöveti expressziójára mutatnak rá, hasonlóan a 
Wsb1-hez, beleértve minkét ligáz hiányát a pajzsmirigyben. Igazoltuk, hogy a MARCH6 
szerepe a D2 szabályozásában fehérje-fehérje interakción alapul. Ezen interakció a 
MARCH6 N-terminusa és a D2 globuláris doménje között jön létre és – a WSB1-hez 
hasonlóan – T4-re érzékeny, vagyis mindkét ligáz részt vesz a D2 szubsztrát-közvetítette 
inaktiválásában. 
 Kiméra dejodázok létrehozásával azonosítottuk a szerkezeti elemek azon minimális 
kombinációját, amely szükséges és elégséges egy dejodáz enzim instabilizálásához és 
ubikvitinációjához. E mellett a két ligáz kötőhelyében különbségeket találtunk. Fehérje-
fehérje interakciós vizsgálatokkal szoros kapcsolatot tártunk fel a D2 ER 
membránextrakciója és deubikvitinációja között, amely a folyamat sebesség-
meghatározó szerepére utal a D2 reverzíbilis ubikvitinációjában. Összefoglalásképpen 
az eredményeink hozzájárulnak az agyi pajzsmirigyhormon hatás kiemelt eleme, a D2 
enzim összetett szabályozásának jobb megértéséhez az agyban.  
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